Page last updated: 2024-08-21

arsenic trioxide and tretinoin

arsenic trioxide has been researched along with tretinoin in 556 studies

Research

Studies (556)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	23 (4.14)	18.2507
2000's	171 (30.76)	29.6817
2010's	265 (47.66)	24.3611
2020's	97 (17.45)	2.80

Authors

Authors	Studies
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Brukštus, A; Čikotienė, I; Kairys, V; Karpavičienė, I; Lebedytė, I; Navakauskienė, R; Raškevičius, V; Valiulienė, G	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Andre, C; Chelbi-Alix, MK; Chen, Z; de The, H; Degos, L; Dhumeaux, D; Guillemin, MC; Herve, L; Koken, MH; Quignon, F; Wang, ZY; Zhu, J	1
Cai, X; Chen, GQ; Chen, SJ; Chen, Z; de The, H; Han, ZG; He, KL; Jia, PM; Kitamura, K; Liu, MM; Ma, J; Miller, W; Naoe, T; Ni, JH; Niu, C; Paul, P; Shi, GY; Shi, XG; Tang, W; Wang, ZY; Waxman, S; Xiong, SM; Zhang, P; Zhang, TD; Zhu, J	1
Look, AT	1
Avvisati, G; Davison, K; Fanelli, M; Ferrara, FF; Gambacorti-Passerini, C; Lamph, WW; Lo Coco, F; Miller, WH; Nervi, C; Pelicci, PG; Peschle, C; Riccioni, R; Rosenauer, A; Shao, W; Testa, U; Waxman, S	1
Benoit, G; Chelbi-Alix, MK; Chen, Z; de Thé, H; Giannì, M; Koken, MH; Lanotte, M	1
Avvisati, G; Lo Coco, F; Mandelli, F; Nervi, C	1
Arima, T; Chyuman, Y; Hanada, S; Ishitsuka, K; Makino, T; Shimotakahara, S; Suzuki, S; Takeshita, T; Takeuchi, S; Uozumi, K; Utsunomiya, A	1
Ikeda, Y; Kinjo, K; Kizaki, M; Muto, A; Ueno, H	1
Buzyn, A; Daniel, MT; de Thé, H; Degos, L; Gianni, M; Koken, MH; Licht, J; Minard, P; Varet, B; Zelent, A	1
Vincent, PC	1
Caen, J; Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Guo, WM; Ju, B; Pan, L; Sun, GL; Wang, HL; Wang, ZY; Yao, YY; Zhao, WL; Zhu, J	1
Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R	1
Agis, H; Edelhäuser, M; Fonatsch, C; Geissler, K; Lechner, K; Mitterbauer, G; Seewann, HL; Thalhammer, R; Valent, P; Weltermann, A	1
Haanen, C; Vermes, I	1
Donelli, A; Galimberti, S; Leonardi, G; Luppi, M; Marasca, R; Petrini, M; Torelli, G; Vaccari, P; Zucchini, P	1
Chen, SJ; Chen, Z; Hu, J; Shen, ZX; Sun, GL; Wang, ZY	1
Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Huang, Y; Jia, PM; Shen, YL; Wang, ZY; Xiong, SM; Yu, Y; Zhang, JW; Zhou, L; Zhu, Q	1
Fukuchi, Y; Hata, J; Ikeda, Y; Ito, M; Kinjo, K; Kizaki, M; Muto, A; Nishihara, T; Ueyama, Y; Umezawa, A; Yamato, K	1
Kizaki, M	1
Hoshi, S; Kitamura, K; Kiyoi, H; Koike, M; Naoe, T; Saito, H	1
Hirosawa, S; Kamei, S; Koyama, T; Ohsawa, M; Shibakura, M	1
Chang, IY; Huang, MJ; Lin, CP; Lin, WY	1
Chang, IY; Huang, MJ; Lin, WY; Sheu, YT	1
Hayashi, T; Imanaka, T; Ishii, K; Komatsu, H; Nakamura, F; Ono, Y; Sawada, H; Tanaka, Y	1
Camacho, LH; Chanel, S; Ellison, R; Heller, G; Ho, R; Scheinberg, DA; Soignet, SL; Warrell, RP	1
Warrell, RP	1
He, LZ; Pandolfi, PP; Rego, EM; Wang, ZG; Warrell, RP	1
Hess, JL; Westervelt, P; Zhang, T	1
Bondesson, L; Garwicz, S; Jönsson, C; Ljungberg, J; Ora, I; Pâhlman, S; Pörn-Ares, I	1
Calleja, EM; Warrell, RP	1
Chen, GQ; Chen, Z; Jing, Y; Miller, WH; Wang, L; Waxman, S; Xia, L	1
Powell, BL	1
Cobcroft, R; Gill, D; Kennedy, GA; Marlton, P	1
Guo, W; Wang, H; Zhao, W	2
Cai, X; Jia, P; Shi, X	1
Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Wu, F; Zhao, W	1
Zelent, A	1
Altucci, L; Chomienne, C; Gronemeyer, H; Raffelsberger, W; Reitmair, A; Rossin, A	1
Al-Hashimi, S; Bazarbachi, A; Bazzi, R; Darwiche, N; de Thé, H; El-Sabban, M; Hermine, O; Nasr, R	1
Au, WY; Chan, GC; Chim, CS; Ho, WK; Kwong, YL; Ooi, GC; Shek, TW	1
Pandolfi, PP	1
Huang, X	2
Chelbi-Alix, MK; de Thé, H	1
Chen, GQ; Chen, SJ; Chen, Z; Wang, ZG; Wang, ZY; Zhang, TD	1
de Thé, H; Lallemand-Breitenbach, V; Zhu, J	1
Guo, W; Wang, H; Zhu, J	1
De Santis, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petrucci, MT; Petti, MC; Pinazzi, MB; Romano, A; Tafuri, A	1
Chen, Z; Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Zhao, W	1
Hu, J; Li, X; Shen, Z; Sun, G; Sun, H; Wang, Z; Wu, W	1
Bi, K; Jiang, G; Tang, T	1
Cai, X; Chen, G; Chen, S; Huang, X; Jia, P; Shen, Y; Wang, L; Wang, Z; Yang, J; Yu, Y; Zhang, X; Zhou, L; Zhou, Y	1
Guo, W; Ju, B; Wang, H; Wang, X; Zhao, W; Zhu, J	1
Cai, X; Huang, X; Zhou, Y	1
Shen, Z; Wang, H; Wang, X; Wu, F; Zhao, W	1
Qiao, Z; Yang, L; Zhang, X	1
Chen, G; Pan, L; Zhou, L	1
Feusner, JH; Nabhan, C; Rowe, JM; Tallman, MS	1
Douer, D	1
Akiyama, H; Fukuhara, O; Hiruma, K; Maeda, Y; Mikoshiba, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Takei, N; Takeshita, A	1
Chu, H; Guo, W; Pan, L; Qu, B; Wang, H; Wang, X; Zhao, W; Zhu, J	1
Chen, F; Li, Y; Xu, G; Zhang, M	1
Au, WY; Chim, CS; Kwong, YL; Liang, R; Lie, AK	1
Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Satoh, H; Shigeno, K; Shinjo, K; Takeshita, A; Terada, H; Yoshida, H	1
Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S	1
Tallman, MS	6
DiPersio, JF; Ley, TJ; Ma, MK; Oldfather, KM; Pollock, JL; Walter, MJ; Westervelt, P; Williams, A	1
Jing, Y; Waxman, S; Xia, L	1
Lopez-Berestein, G; Ozpolat, B	1
Nabhan, C; Tallman, MS	1
Guo, P; Hu, Y; Qiao, Z; Shen, G; Song, S; Wang, J; Yang, L; Zhang, X; Zhou, H	1
Daniel, MT; De Thé, H; Degos, L; Dombret, H; Gourmel, B; Guillemin, MC; Janin, A; Kogan, S; Lallemand-Breitenbach, V; Lanotte, M; Raffoux, E; Soilihi, H; Vitoux, D; Zhu, J	1
Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK	1
Li, B; Lou, FD; Wang, YZ; Yao, SQ; Yu, L; Zhu, HL	1
Cai, X; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q	1
Cao, Q; Chen, SJ; Chen, X; Chen, Z; Liu, YF; Shen, ZX; Wang, AH; Wang, ZY; Zhu, YM	1
Li, DP; Li, HQ; Li, R; Qi, JY; Qian, LS; Wan, CC; Wang, ZQ; Zhao, YZ; Zhou, CL	1
Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Rossi, M; Visani, G	1
DiPersio, J; Douer, D; Giralt, S; Hu, W; Lill, M	1
Buzyn, A; Cassinat, B; Chomienne, C; Cimerman, P; Daniel, MT; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lebbé, G; Poupon, J; Raffoux, E; Réa, D; Rousselot, P; Taksin, AL; Tibi, A	1
Au, WY; Chan, GC; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Mak, R	1
Stull, DM	1
Grigg, A; Kimber, R; Szer, J	1
Udvardy, M	1
Benoit, G; Bobé, P; Canova, A; Chelbi-alix, MK; Pine, R	1
Takeshita, A	1
Chen, SJ; Chen, Y; Chen, Z; De Thé, H; Fang, J; Gu, BW; Li, JM; Liu, YF; Shen, Y; Shen, ZX; Shi, JY; Shi, ZZ; Tang, W; Wang, ZY; Waxman, S; Wu, W; Yan, H; Zheng, PZ; Zhu, YM	1
Bradley, D	1
Hong, WD; Li, J; Li, QH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D	1
Cannizzaro, L; Ding, W; Gallagher, RE; Guidez, F; Kim, SH; Paietta, E; Ramesh, KH; Sun, Y; Warrell, RP; Zelent, A; Zhou, DC	1
Jing, Y	1
Dryden, MJ; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; Pierce, S; Ratnam, S; Tsimberidou, AM; Whitman, GJ	1
Feusner, J; Gregory, J; Ravindranath, Y	1
Cai, L; Cui, J; Gao, S; Jiang, Z; Li, W; Liu, Z; Song, Y; Wang, G; Yang, Y; Yao, C; Yuan, CJ	1
Li, J; Shen, T; Wang, X; Xu, CM; Yang, Y; Zhang, ZN; Zuo, L	1
Kwong, YL	2
Civallero, M; Cosenza, M; Marcheselli, R; Pozzi, S; Sacchi, S	1
Chen, G; Chen, L; Chen, S; Li, X; Ni, J; Shen, Z; Tang, W; Wang, Z; Xiong, S; Zhong, H; Zhu, J	1
Du, J; Liu, BR; Qian, XP; Wang, LF; Yin, HT; Zou, ZY	1
Benecke, A; Cayre, YE; Denis, FM; Di Gioia, Y; Lutz, PG; Touw, IP	1
Bastien, J; Bauer, A; Bruck, N; Gianni, M; Rochette-Egly, C; Tarrade, A	1
Ikeda, T; Kimura, F; Kufe, D; Motoyoshi, K; Nakata, Y; Ogura, K; Sato, K; Sporn, M	1
Beal, N; Diehl, LF; Huff, CA; Jones, RJ; Matsui, W; Smith, BD; Vala, M	1
Chen, SJ; Zhao, WW	1
Auffray, C; Chen, SJ; Chen, YL; Chen, Z; Du, YZ; Eveno, E; Fan, HY; Huang, QH; Imbeaud, S; Jin, G; Shen, SH; Wang, KK; Waxman, S; Xiao, DK; Zhang, J; Zhang, QH; Zhang, QY; Zhao, CJ; Zheng, PZ	1
Horii, T; Maekawa, M; Matsui, H; Naito, K; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Shirai, N; Takeshita, A	1
Cui, JW; Gao, SJ; Jiang, ZY; Li, W; Liu, ZL; Song, YQ; Wang, GJ; Yang, Y; Yao, C; Yuan, CJ	1
Aradi, J; Dudognon, C; Hillion, J; Lanotte, M; Pendino, F; Ségal-Bendirdjian, E; Tarkanyi, I	1
Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A	1
Chen, SJ; Chen, Z; Zhou, GB	1
Hu, Y; Qiao, Z; Song, S; Yang, L; Zhang, X; Zhou, H	1
Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A	1
Li, BX; Lin, DH; Lin, LM; Xiao, JB; Yang, BF	1
Tamm, I	1
Chen, GQ; Huang, Y; Jiang, Y; Peng, ZG; Wu, YL; Yan, H; Yu, Y; Zhao, Q; Zhu, YS	1
Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Jones, D; Kantarjian, H; Verstovsek, S	1
Frankfurt, O; Tallman, MS	1
Benedusi, M; Bertagnolo, V; Bovolenta, M; Brugnoli, F; Capitani, S; Miscia, S	1
Ades, L; Bordessoule, D; Castaigne, S; Chevret, S; de Botton, S; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Guerci, A; Kelaidi, C; Link, H; Meyer-Monard, S; Raffoux, E; Rayon, C; Rigal-Huguet, F; Sanz, M; Stoppa, A; Thomas, X; Vekhoff, A	1
Jing, Y; Waxman, S; Wurmbach, E; Xia, L	1
Fukai, Y; Hirata, M; Ichikawa, N; Kaise, T; Kinoshita, K; Kobayashi, H; Ohta, S; Saitoh, H; Sakurai, T; Ueno, M	1
Caillot, D; Fenaux, P; Huguet, F; Pigneux, A; Raffoux, E; Thomas, X	1
Kai, T; Kimura, H; Maruyama, Y; Ogawa, K; Sato, H; Shiga, Y	1
Deng, SH; Han, MZ; Li, QC; Li, X; Li, Y; Li, YT; Li, ZJ; Qiu, LG; Wan, CC; Yang, RC; Zhao, YZ	1
Duan, LN; Guo, ZK; Ji, SQ; Wang, HX	1
Kwong, YL; Leung, J; Pang, A; Tse, EW; Yuen, WH	1
Ohnishi, K	2
Chang-chun, W; Jian-xiang, W; Lu-gui, Q; Ming-zhe, H; Qiao-chuan, L; Ren-chi, Y; Wan-jun, S; Xin, L; Yan, L; Yao-zhong, Z; Yun-tao, L; Zeng-jun, L	1
Ewer, MS; Jones, RL	1
Estey, E; Kantarjian, H; Keating, MJ; Tsimberidou, AM	1
Avvisati, G; Breccia, M; Buffolino, S; Cimino, G; De Angelis, G; Lo-Coco, F; Mariella, M; Martini, V; Minotti, C	1
Jing, Y; Waxman, S	1
Bi, KH; Jiang, GS	1
Akar, U; Berestein, GL; Colburn, N; Danilenko, M; Kornblau, S; Ozpolat, B; Steiner, M; Tirado-Gomez, M; Zorrilla-Calancha, I	1
Chen, SJ; Chen, Z; Wang, ZY; Zhang, J; Zhou, GB	1
Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA	1
Ammatuna, E; Lo Coco, F; Sanz, MA	1
Beissert, T; Bug, G; Henschler, R; Hoelzer, D; Puccetti, E; Rüster, B; Ruthardt, M; Seshire, A; Zheng, X	1
Besançon, F; Mathieu, J	1
de The, H; Nasr, R; Vitoux, D	1
Guo, T; Hong, M; Hu, Y; Shen, GX; Song, SJ; Wei, WN; Xia, LH; Zhang, XH	1
Berridge, MV; Herst, PM; Hesketh, EL; Ritchie, DS	1
Berman, JN; Look, AT	1
Farhat, M; Venugopal, P	1
Ma, J	1
Albihn, A; Henriksson, M; Jiang, G; Tang, T; Tian, Z	1
Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K	1
Chen, GQ; Wang, LS; Wu, YL; Yu, Y	1
Chen, SJ; Chen, Z; Li, G; Zhou, GB	1
Chen, SY; Dong, Y; Guo, WJ; Ma, LH; Wang, ZY	1
Dai, CW; Pei, MF; Shen, JK; Xu, YX; Zhang, GS; Zheng, WL	1
Cunha De Santis, G; Cunha, FQ; Faccioli, LH; Falcão, RP; Garcia, AB; Lima, AS; Moreno, SE; Rego, EM; Secco, D; Sousa, RB; Tamarozzi, MB	1
Li, D; Wei, F; Zhang, W; Zhang, X	1
Estey, E; Kopp, L; Quezada, G; Wells, RJ	1
Chen, Z; Wang, ZY	1
Bazarbachi, A; de Thé, H; Habib, A; Hamade, E; Mahfouz, R; Nasrallah, MS	1
Isobe, Y; Oshimi, K; Sasaki, M; Sugimoto, K	1
Chen, X; Chen, Y; Zhang, L; Zhao, H; Zhu, X; Zou, Y	1
Acevedo-Alvarez, M; Akar, U; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejia, P; Zorrilla-Calancha, I	1
Ammatuna, E; Lo-Coco, F; Montesinos, P; Sanz, MA	1
Grzanka, A; Izdebska, M; Litwiniec, A; Szczepański, MA	1
Dalley, CD; Ezaydi, Y; Goepel, JR; Kirkbride, P; Krishna, R; Smith, DJ; Snowden, JA; Sorour, Y	1
Horikoshi, A; Iriyama, N; Kaise, T; Miyashita, SI; Shikino, O; Toyoda, H; Yoshino, Y; Yuan, B	1
Abreu e Lima, RS; Falcão, RP; Freitas, RA; Garcia, AB; Gimenes Teixeira, HL; Jordão, AA; Lima, AS; Lucena-Araujo, AR; Rego, EM; Scheucher, PS; Silva dos Santos, GA; Vannucchi, H	1
Cheng, YF; Liu, CF; Liu, GL; Lu, AD; Wang, B; Zhang, LP	1
Altman, JK; Tallman, MS	2
Haferlach, T	1
Blamble, D; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Fiorentino, J; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Verstovsek, S; Wierda, W	1
Fang, H; Wang, K; Zhang, J	1
Brossart, P; Fröhlich, E; Wahl, R	1
Kogan, SC	1
Chen, B; Chen, QS; Chen, SJ; Chen, Z; Hu, J; Li, JM; Liu, YF; Shen, ZX; Sun, HP; Tang, W; Wang, ZY; Waxman, S; Wu, CF; Wu, W; Xu, F; Zelent, A; Zhao, WL; Zhou, GB; Zhu, YM	1
Cao, YX; Dai, CW; Li, RJ; Pei, MF; Peng, HL; Shen, JK; Xu, YX; Yang, JJ; Yi, Y; Zhang, GS; Zheng, WL; Zhong, HY	1
Tang, DZ; Tao, S; Zhou, K	1
Petrie, K; Waxman, S; Zelent, A	1
Lu, DP; Zhang, M; Zhao, XH; Zhu, HJ	1
Angell, R; Aslett, H; Batson, E; Burnett, AK; Clark, RE; Diverio, D; Flora, R; Grimwade, D; Hills, RK; Jones, K; Jovanovic, JV; Lo-Coco, F; Nugent, EA; Patel, Y; Rennie, K; Solomon, E; Wheatley, K	1
Duggan, J; Siderov, J	1
Ravandi, F	3
Dai, L; Liu, YH; Ruan, CG; Shen, WH; Wang, ZY; Zhang, W	1
Kurokawa, M; Nagai, S; Takahashi, T	2
Balasubramanian, P; Chandy, M; Chendamarai, E; George, B; Lakshmi, KM; Mathews, V; Srivastava, A; Thirugnanam, R; Viswabandya, A	1
de Witte, TJ; Jansen, JH; Linssen, PC; Luesink, M; Muus, P; Pennings, JL; Pfundt, R; van der Reijden, BA; Wissink, WM	1
Feusner, J; Gregory, J	1
Leu, L; Mohassel, L	1
Chen, JP; Liu, JP; Xia, Y; Xu, SN	1
Li, L; Zhang, ZH; Zhao, WD	1
Duan, MH; Han, B; Jiao, L; Shen, T; Wang, SJ; Xu, Y; Zhang, W; Zhao, YQ; Zhou, DB; Zhu, TN; Zhuang, JL; Zou, N	1
Hatta, Y; Hirabayashi, Y; Ishizuka, H; Kobayashi, Y; Takei, K; Takeuchi, J; Tanaka, T	1
Fukushima, N; Hisatomi, T; Ide, M; Itamura, H; Kimura, S; Sueoka, E; Tanaka, M; Tomimasu, R; Urata, C; Yokoo, M	1
Arceci, R; Dauses, T; Devetten, M; Gallagher, RE; Gojo, I; Gore, SD; Jamieson, K; Morris, L; Owoeye, I; Redner, RL; Schachter-Tokarz, E; Sekeres, MA	1
Cao, F; Gilbert, GE; Heegaard, CW; Hou, J; Rasmussen, JT; Shi, J; Zhang, Y; Zhou, J	1
Altman, JK; Dolniak, B; Glaser, H; Goussetis, DJ; Kroczynska, B; McNeer, JL; Platanias, LC; Sassano, A	1
Ferrara, F	1
Grimwade, D; Guidez, F; Mistry, AR; Solomon, E	1
Arora, N; Das, R; Malhotra, P; Nath, A; Patel, FD; Varma, N; Varma, S	1
de Thé, H; Nasr, R	1
Bian, S; Hao, L; Li, J; Wang, H; Wang, X; Wu, Q	1
Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM	1
Bjørås, M; Bøe, SO; Isakson, P; Simonsen, A	1
Bloom, SE; Bunaciu, RP; Nayak, S; Shen, M; Varner, JD; Yen, A	1
Appelbaum, FR; Couban, S; Coutre, S; Feusner, JH; Gallagher, RE; Gregory, J; Larson, RA; Moser, B; Powell, BL; Rowe, JM; Stock, W; Stone, RM; Tallman, MS; Willman, CL	1
Bøe, SO; Simonsen, A	1
Cortes, J; Dayyani, F; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F	1
Chung, JG; Huang, WW; Kuo, SC; Lai, IC; Lai, TY; Lin, CC; Lin, JJ; Wen, YF; Yang, JS	1
Fu, CC; Jin, ZM; Liang, JY; Liu, YJ; Ma, X; Qiu, HY; Tang, XW; Wu, DP	1
Douer, D; Gore, S; Powell, BL; Ranganathan, A; Ravandi, F; Rowe, J; Sanz, MA; Tallman, M	1
Hasan, SK; Lo-Coco, F	2
Dai, L; Jiang, M; Liu, Y; Ruan, C; Wang, Z; Wu, D; Zhang, W	1
Lo-Coco, F; Sanz, MA	1
Manji, GA; Tallman, MS	1
Gong, YP; Luo, S; Yang, L; Yang, YM	1
Chen, X; Chen, Y; Zhang, L; Zhu, X; Zou, Y	1
Rogers, JE; Yang, D	1
Gore, SD; Prebet, T	1
Chen, Z; Jin, J; Li, K; Mei, C; Tong, H; Wang, H	1
Anderson, LD; Collins, RH; Kirk, A; Levitt, D; Naina, HV; Scaglioni, PP; Vusirikala, M	1
Alimoghaddam, K; Ghaffari, H; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Jalili, M; Mousavi, A; Rostami, S	1
Geng, XX; Ma, R; Quan, LN; Tang, LP	1
Estey, EH; Hutchinson, F	1
Breccia, M; Cicconi, L; Giannì, L; Latagliata, R; Lo-Coco, F; Minotti, C	1
Chen, HZ; Chen, XY; Qi, H; Rong, ZX; Wang, BS; Wang, H	1
Akashi, K; Harada, M; Kamimura, T; Miyamoto, T	1
Shinagawa, K	1
Abreu e Lima, RS; Curti, C; de Thé, H; dos Santos, GA; Falcão, RP; Gimenes-Teixeira, HL; Lima, AS; Lucena-Araujo, AR; Nasr, R; Pandolfi, PP; Pestana, CR; Rego, EM; Rodrigues, FP; Santana-Lemos, BA; Scheucher, PS; Thomé, CH; Uyemura, SA	1
Park, JH; Tallman, MS	1
Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY	1
Gurung, A; Huang, BT; Li, BS; Xiao, Z; Zeng, QC; Zhao, WH	1
Mi, J	1
Brenneman, MA; Chen, JD; Denissova, NG; Hakhverdyan, Z; Nasello, C; Yeung, PL	1
Inoue, A; Kawakami, C; Takitani, K; Tamai, H	1
Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ	1
Chen, Y; Li, Z; Lu, Q	1
Chen, P; Chen, YZ; Huang, HF; Lin, ZX; Lu, R; Wu, Y	1
Cao, Z; Li, Q; Ruan, M; Wang, J; Zhang, L; Zhu, X; Zou, Y	1
Chen, SJ; Chen, Z; Li, JM; Mi, JQ; Shen, ZX	1
Benoilid, A; Broly, F; Echaniz-Laguna, A; Fornecker, LM; Goullé, JP; Lannes, B; Mousson de Camaret, B; Vinzio, S	1
Breccia, M; Lo-Coco, F	1
Huang, H; Liu, H; Qin, Y; Teng, R; Xu, M; Xu, R; Yang, L; You, X	1
Guo, WW; Liu, WJ	1
Choudhry, A; DeLoughery, TG	1
Arcese, W; Aversa, F; Bacigalupo, A; Breccia, M; Camboni, A; Cupelli, L; Di Veroli, A; Iori, AP; Lo-Coco, F; Papayannidis, C; Ramadan, SM	1
Chen, Y; Cortes, J; Kantarjian, H; Ravandi, F; Wang, H	1
Chen, SJ; Zhou, GB	1
Bashford, J; Bradstock, K; Browett, P; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C	1
Stein, EM; Tallman, MS	1
Chang, MC; Chang, YF; Chen, CG; Chiang, YH; Hsieh, RK; Lim, KH; Lin, HC; Lin, J	1
Park, JH	1
Aizawa, S; Hatta, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B	1
Chen, YZ; Li, XF; Liao, XY; Wu, Y; Yang, JH	1
Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y	2
Aul, C; Berdel, WE; Braess, J; Büchner, T; Erben, P; Haferlach, C; Haferlach, T; Hanfstein, B; Hehlmann, R; Heinecke, A; Hiddemann, W; Hofmann, WK; Horst, HA; Kreuzer, KA; Krug, U; Lengfelder, E; Müller-Tidow, C; Sauerland, C; Schneider, S; Schnittger, S; Schultheis, B; Serve, H; Spiekermann, K; Wörmann, B	1
Chen, P; Chen, YZ; Huang, HF; Lu, R; Wu, Y	1
Cao, J; Chen, D; Chen, L; Du, X; Fan, Z; Li, S; Lin, L; Liu, X; Ma, J; Pei, R; Sha, K; Tang, S; Wu, J; Ye, P; Zhang, B; Zhang, P	1
Chen, MH; Liu, M; Liu, TB; Xle, JM; Yang, AQ; Yang, P	1
Attarbaschi, A; Boztug, H; Chen, HY; Cooper, BW; Dworzak, MN; König, M; Strehl, S; Suzukawa, K; Zhang, SJ	1
Chen, H; Liu, J; Liu, L; Liu, M; Shi, B; Ye, L; Yu, L; Zhang, Y	1
Iland, HJ; Seymour, JF	1
Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX	1
Belin, E; Chesnut, G; Taylor, S	1
Kiyoi, H; Naoe, T; Tomita, A	1
Hofmann, WK; Lengfelder, E; Nolte, F	2
Fan, H; Li, S; Lin, J; Lu, X; Zhu, H	1
Jia, XH; Liu, JQ; Wang, KK; Wang, P; Xi, WD; Yang, XW; Zhang, H	1
He, Y; Huang, S; Mao, C; Qin, X; Sun, X; Zhu, L	1
Chen, M; Liu, T; Niu, T; Wang, L; Xie, LP; Zeng, K; Zou, XL	1
Asou, N; Fujita, H; Hyo, R; Inaguma, Y; Ishigatsubo, Y; Iwanaga, M; Izumi, T; Kiyoi, H; Matsuda, M; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Nomura, S; Ohnishi, K; Ohtake, S; Okada, M; Shinagawa, K; Takeshita, A; Yamauchi, T	1
Amadori, S; Avvisati, G; Brandts, CH; Breccia, M; Carella, AM; Cazzola, M; Cerqui, E; Cicconi, L; Ciceri, F; Di Bona, E; Divona, M; Döhner, H; Döhner, K; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Finizio, O; Fioritoni, G; Ganser, A; Hänel, M; Hertenstein, B; Iacobelli, S; Kropp, MG; La Nasa, G; Levis, A; Link, H; Lo-Coco, F; Lübbert, M; Luppi, M; Mandelli, F; Melillo, L; Morra, E; Orlando, SM; Platzbecker, U; Rambaldi, A; Salih, HR; Sauer, M; Schlenk, RF; Schmitz, N; Sica, S; Specchia, G; Thiede, C; Venditti, A; Vignetti, M; von Lilienfeld-Toal, M; Wattad, M	1
Chen, SJ; Chen, Z	2
Chen, X; Shao, J; Yan, J	1
Kuo, TC; Tian, TF; Tseng, YJ	1
de Thé, H; Lallemand-Breitenbach, V	1
Mehta, SV; Shukla, SN; Vora, HH	1
Fung, TK; So, CW	1
Chen, Z; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Wang, Y; Ye, X	1
Iacoboni, G; Montesinos, P; Sanz, MA	2
Cheng, Y; Liu, G; Lu, A; Wang, B; Wu, J; Zhang, L	1
Mayor, S	1
Chen, L; Hu, X; Wang, J; Xu, X	1
Hasan, SK; Lo-Coco, F; Montesinos, P; Sanz, MA	1
Chen, SJ; Huang, XJ; Jiang, H; Jin, J; Li, JY; Ma, J; Wang, JX; Wu, DP; Zhu, HH	1
Douer, D; Ganzel, C; Tallman, MS	1
Dos Santos, GA; Kats, L; Pandolfi, PP	1
Macheta, A; Podhorecka, M	1
Albert, L; Jhanwar-Uniyal, M; Karsy, M; Murali, R	1
Ablain, J; de Reynies, A; de Thé, H; Minucci, S; Rice, K; Soilihi, H	1
Breccia, M; Cicconi, L; Lo-Coco, F	2
Ansari, M; Bourquin, JP; Gumy-Pause, F; Huezo-Diaz, P; Judas, C; Mattiello, V; Rock, N	1
Altman, JK; Appelbaum, FR; Attar, EC; Coutre, SE; Gore, SD; Kopecky, KJ; Larson, RA; Levitan, D; Maher, T; Othus, M; Paietta, E; Powell, B; Stock, W; Tallman, MS; Wetzler, M; Willman, CL	1
Chen, L; Gao, L; Hu, X; Lü, S; Song, X; Wang, J; Yang, J; Zhang, W	1
Montesinos, P; Sanz, MA	1
de Thé, H; Rice, KL	1
Altman, JK; Cull, EH	1
Cicconi, L; Lo-Coco, F	2
Chen, P; Chen, YZ; Huang, HF; Wu, JY	1
Guan, X; Li, C; Li, M; Shu, X; Sun, Y	1
Cull, EH; Kwaan, HC	1
Garnier, N; Miller, WH; Nichol, JN	1
Iland, HJ; Seymour, JF; Wei, A	1
Grimwade, D; Hills, RK; Jovanovic, JV	1
Douer, D; Ganzel, C	1
Feusner, JH; Gregory, J; Kutny, MA	1
Komatsu, N	1
Chen, S; Chen, Z; Hu, J; Li, J; Mi, J; Wang, Z; Zhu, H	1
Cheong, HJ; Jung, YS; Kim, KH; Kim, SJ; Lee, N; Park, HS; Won, JH	1
Breccia, M; Efficace, F; Foà, R; Latagliata, R; Lo Coco, F; Minotti, C; Molica, M	1
Buc Calderon, P; Felipe, KB; Glorieux, C; Kviecinski, MR; Sandoval, JM; Sid, B; Stockis, J; Valenzuela, M; Verrax, J	1
Liu, F; Wang, W; Wei, J; Ye, C	1
Cortes, J; Daver, N; Eghtedar, A; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Rodriguez, I	1
Fang, ZG; He, Y; Hu, Y; Huang, RW; Li, XD; Lin, DJ; Liu, JJ; Liu, Q; Long, ZJ; Wang, DN; Xiao, RZ; Yan, JS	1
Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH	1
He, Y; Hu, Y; Huang, R; Li, X; Wang, D; Wang, W; Xiao, R; Zhang, E	1
Bally, C; de Thé, H; Lehmann-Che, J	1
Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Cottone, F; Di Bona, E; Efficace, F; Ferrara, F; Finizio, O; Fioritoni, G; Kropp, MG; Levis, A; Lo-Coco, F; Mandelli, F; Platzbecker, U; Schlenk, RF; Sica, S; Specchia, G; Vignetti, M	1
Arteaga, MF; Fung, TK; Mikesch, JH; So, CW	1
Ablain, J; de Reynies, A; de Thé, H; Halftermeyer, J; Le Bras, M; Metzger, D; Peres, L; Vitaliano-Prunier, A	1
Gore, SD; Zeidan, AM	1
Fujita, H	1
Anderlini, P; Borthakur, G; Brandt, M; Cortes, J; Daver, N; Dinardo, C; Ferrajoli, A; Garcia-Manero, G; Hosing, C; Kadia, T; Kantarjian, H; Marcucci, G; O'Brien, S; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Verstovsek, S	1
Nitto, T; Sawaki, K	1
Barakat, S; Couban, S; Lachaine, J; Mathurin, K	1
Brunetti, L; Di Raimondo, F; Falini, B; Gionfriddo, I; Martelli, MP; Mezzasoma, F; Milano, F; Mulas, F; Pacini, R; Pettirossi, V; Pierangeli, S; Rossi, R; Sportoletti, P; Tabarrini, A; Tiacci, E; Vetro, C	1
Ades, L; Bazarbachi, A; Berthier, C; Darwiche, N; Dassouki, Z; de Thé, H; Dombret, H; El Hajj, H; Fenaux, P; Hleihel, R; Legrand, O; Mohty, M; Raffoux, E; Sahin, U; Salameh, A; Tawil, N; Zibara, K	1
Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Chomienne, C; Ganesan, S; George, B; Janet, NB; Kamath, V; Lakshmi, KM; Mathews, V; Mugasimangalam, R; Mullapudi, N; Nair, SC; Nellickal, AJ; Padua, RA; Srivastava, A; Srivastava, V; Viswabandya, A	1
Inomata, T; Sunami, K	1
Guo, QL; Jiang, NJ; Liu, WJ; Xu, Q	1
Coombs, CC; Tallman, MS; Tavakkoli, M	1
Ma, H; Yang, J	1
Bernardi, R; Coltella, N; Ponente, M; Ponzoni, M; Valsecchi, R	1
Jin, J; Li, F; Lu, Y; Mai, W; Meng, H; Mu, Q; Pei, R; Qian, W; Tong, H; Yu, M; Zhao, X	1
Chen, SJ; Chen, Z; Mi, JQ; Yan, XJ; Zhou, GB	1
de Thé, H	2
Allen, SL; Altman, JK; Cortes, JE; Coutre, S; Di Bona, E; Kantarjian, H; Lo-Coco, F; Ravandi, F; Sanford, D; Sanz, MA; Wetzler, M	1
Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Pathak, A; Wildner, R	1
Chen, B; Chen, C; Chen, L; Chen, SJ; Chen, Z; Fu, YK; Gu, ZH; Hu, J; Jin, J; Li, JM; Lou, YJ; Mi, JQ; Shen, Y; Shen, ZX; Shi, JY; Wang, ZY; Zhao, WL; Zhu, HH; Zhu, HM; Zhu, YM	1
Clarke, KM; Mills, KI; Young, CS	1
Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Tallman, M; Tang, B; Wildner, R	1
Bowen, D; Burnett, AK; Clark, RE; Friis, L; Grech, A; Grimwade, D; Hills, RK; Hunter, A; Jones, G; Kell, J; Khwaja, A; Knapper, S; Lok, J; McMullin, MF; Morgan, YG; Russell, NH	1
Han, S; Huang, XJ; Jiang, H; Jiang, Q; Liang, GW; Shi, LW; Zhu, HH	1
Cottone, F; Efficace, F; Lo Coco, F; Mandelli, F; Platzbecker, U	1
Aviram, A; Klein, A; Muchtar, E; Oniashvili, N; Parnes, D; Raanani, P; Rabizadeh, E; Shepshelovich, D; Yeshaya, J	1
Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; González-Leal, XJ; Gutiérrez-Aguirre, H; Jaime-Pérez, JC; Pinzón-Uresti, MA	1
Ren, YQ; Wang, LL	1
Matsushita, H	1
Ablain, J; de Thé, H; Esnault, C; Lehmann-Che, J; Poirot, B	1
Kolb, EA; Meshinchi, S	1
Adès, L; Alex, AA; Chomienne, C; Fenaux, P; Ganesan, S; Gorombei, P; Guerenne, L; Krief, P; Mathews, V; Omidvar, N; Padua, RA; Patel, S; Pla, M; Schlageter, MH; West, R	1
Degos, L	1
Khadwal, A; Malhotra, P; Saikia, UN; Yanamandra, U	1
Adachi, K; Honma, Y; Kawakami, K; Miyake, T; Suzumiya, J; Takahashi, T	1
Gerber, JM; Grunwald, MR; Lipford, EH; McDonnell, MH; Smith, ET	1
Li, D; Luo, D; Wu, S; Zhang, Y; Zhou, J	1
Hu, L; Huang, L; Li, C; Meng, F; Tang, Y; Wan, K; Wang, Y; Xu, D; Zhou, J	1
Altman, JK; Norsworthy, KJ	1
Himeno, S; Sumi, D; Suzukawa, K	1
Lo-Coco, F; Testa, U	1
Assaf, C; Beyer, M; Cosagarea, I; Möbs, M; Touba, R; Vandersee, S	1
Di Donato, L; Lo-Coco, F; Schlenk, RF	1
Albano, F; Alfonso, V; Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Ciardi, C; Cicconi, L; Di Bona, E; Divona, M; Ferrantini, A; Ferrara, F; Kropp, MG; Lavorgna, S; Levis, A; Lo-Coco, F; Mandelli, F; Ottone, T; Paoloni, F; Piciocchi, A; Santoro, A; Sborgia, M; Sica, S; Voso, MT	1
Afroze, D; Azad, NA; Aziz, SA; Baba, SM; Dar, FA; Jan, A; Pandith, AA; Shah, ZA	1
Atashrazm, F; Dickinson, JL; Holloway, AF; Lowenthal, RM; Woods, GM	1
Jin, J; Liu, L; Lou, Y; Ma, Y	1
Albano, F; Amadori, S; Avvisati, G; Borlenghi, E; Brandts, CH; Breccia, M; Brossart, P; Cairoli, R; Cicconi, L; Cortelezzi, A; D'Arco, AM; Di Bona, E; Di Renzo, N; Divona, M; Döhner, H; Döhner, K; Efficace, F; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Fozza, C; Frairia, C; Ganser, A; Hänel, M; Hertenstein, B; La Nasa, G; Link, H; Lo-Coco, F; Lübbert, M; Mandelli, F; Melillo, L; Paoloni, F; Platzbecker, U; Pogliani, EM; Rambaldi, A; Röllig, C; Salih, HR; Sborgia, M; Schlenk, RF; Schmitz, N; Thiede, C; Vignetti, M; Wattad, M	1
Béné, MC; Bonnet, A; Chevallier, P; Garandeau, C; Garnier, A; Guillaume, T; Houreau-Langlard, D; Hourmant, M; Le Gouill, S; Moreau, P; Peterlin, P; Tissot, A; Vantyghem, S	1
Cai, Y; Chen, W; Du, X; Huang, J; Lou, J; Sun, M; Wang, Z; Zhang, Q	1
Angelopoulou, MK; Asimakopoulos, JV; Kelepesis, G; Konstantopoulos, K; Koutsi, C; Meletis, J; Papageorgiou, L; Petevi, K; Plata, E; Tsaftaridis, P; Vassilakopoulos, TP	1
Bochennek, K; Creutzig, U; Dworzak, MN; Faber, J; Flotho, C; Graf, N; Kontny, U; Mueller, JE; Reinhardt, D; Rossig, C; Schmid, I; von Neuhoff, C; von Neuhoff, N; von Stackelberg, A	1
Gnadler, M; Hecht, A; Lengfelder, E; Mezger, J	1
Huang, F; Ling, X; Ren, G; Su, Y; Xie, P; Xu, L; Zeng, Z; Zhang, W; Zhang, XK; Zhou, H	1
Pan, J; Zhang, X	1
Gao, N; Li, XZ; Sun, JR; Wang, XX; Yu, WZ	1
Huang, LB; Ke, ZY; Li, Y; Liu, XJ; Luo, XQ; Tan, HZ; Tang, YL; Wang, LN; Zhang, YC; Zhang, ZH	1
Chavda, SJ; Koh, M; Lindsay, S; Willis, F	1
Dunoyer-Geindre, S; Kruithof, EKO; Lecompte, T; Rivier-Cordey, AS; Tsopra, O	1
Chen, J; Dai, J; Guo, H; Liu, X; Yan, L; Yu, S; Zhang, W; Zhu, J	1
Banella, C; Blandino, G; Capuano, E; De Panfilis, S; Divona, M; Fazi, F; Fontemaggi, G; Lo-Coco, F; Masciarelli, S; Noguera, NI; Ottone, T; Picardi, A	1
Boddu, P; Ferrajoli, A; Jain, N; Kadia, T; Pemmaraju, N; Ravandi, F; Schlette, E; Tang, G; Thakral, B; Wierda, W	1
Chen, S; Lv, X; Yu, J; Zhang, L	1
Federzoni, EA; Humbert, M; Tschan, MP	1
Brossart, P; Gembruch, U; Giovannini, G; Janzen, V; Mayer, K; Merz, WM; Nellessen, CM	1
Carcelero San Martín, E; Creus Baró, N; Riu Viladoms, G	1
Guo, ZP; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Zhu, HH	1
Chen, C; Huang, JB; Liu, ZL; Wang, J; Xu, HG; Xue, HM; Zhang, BH	1
Kjeldsen, E; Nørgaard, JM; Stentoft, J; Tøstesen, M; Østgård, LSG	1
Kjeldsen, E; Nørgaard, JM; Stentoft, J; Tøstesen, M; Østergård, LSG	1
Aliabadi, LS; Alimoghaddam, K; Fumani, HK; Ghavamzadeh, A; Jahani, M; Jalili, M; Mousavi, SA; Rostami, S; Vaezi, M; Yaghmaie, M	1
Balme, B; Carlioz, V; Collinge, E; Gerland, LM; Paubelle, E; Salles, G; Sujobert, P; Thomas, X; Tigaud, I	1
Chen, X; Luo, Z; Pei, Y; Sun, W; Tong, Q; Wang, K; You, H; Yuan, M; Zhang, Y; Zhao, X; Zhu, H	1
Au, WY; Chan, TSY; Gill, H; Hwang, YY; Ip, HW; Kho, B; Kumana, CR; Kwong, YL; Lau, JSM; Lee, HKK; Li, W; Lin, SY; Mak, V; Tse, E; Yim, R; Yip, SF	1
Bøe, SO; Eriksson, J; Lång, A; Lång, E; Rowe, AD; Øye, A	1
Karunakaran, P; Khadwal, A; Lad, D; Malhotra, P; Nampoothiri, RV; Naseem, S; Prakash, G; Sinha, A; Varma, N; Varma, S; Yanamandra, U	1
An, W; Chang, L; Chen, X; Chen, Y; Guo, Y; Liu, F; Liu, T; Liu, X; Qi, B; Ren, Y; Ruan, M; Wang, S; Yang, W; Zhang, J; Zhang, L; Zhu, X; Zou, Y	1
Imagawa, J	1
Balasubramanian, P; Goni, D; Malhotra, P; Nampoothiri, RV	1
Kayser, S; Platzbecker, U; Schlenk, RF	1
Ades, L; Bally, C; Berthier, C; Cassinat, B; de Thé, H; Fenaux, P; Hirsch, P; Jollivet, F; Kogan, S; Lehmann-Che, J; Letouzé, E; Mozziconacci, MJ; Pigneux, A; Yuan, H	1
Chen, LM; Gong, S; Liu, X; Liu, Y; Wang, HY; Wang, MC; Xi, JY; Zhang, HY; Zhang, XX	1
Alfonso, V; Breccia, M; Cicconi, L; Diverio, D; Divona, M; Foa, R; Franceschini, L; Iaccarino, L; Latagliata, R; Lo-Coco, F; Molica, M; Ottone, T; Rizzo, M; Voso, MT	1
Chen, M; Gan, LG; Li, LW; Liu, BZ; Liu, L; Shan, ZL; Xiao, CL; Xu, T; Yao, SF; Zhao, Y; Zhong, L	1
Cuccurullo, R; Diverio, D; Girardi, K; Gurnari, C; Lo-Coco, F; Locatelli, F; Micalizzi, C; Putti, MC; Santoro, N; Strocchio, L; Testi, AM; Zecca, M	1
Chen, CH; Chen, Y; Dhe-Paganon, S; Doctor, ZM; Gao, ZJ; Herbert, MK; Jackson, BP; Kozono, S; Lian, X; Lin, YM; Lu, KP; Massefski, W; Pinch, B; Qiu, C; Seo, HS; Tan, L; Zhou, XZ	1
Betteridge, S; Burnett, A; Dennis, M; Dillon, R; Grimwade, D; Hills, R; Jovanovic, J; Russell, N	1
Chen, GH; Chen, HQ; Feng, X; Huang, K; Huang, LB; Ke, ZY; Li, B; Li, J; Liu, RY; Luo, JS; Luo, XQ; Mai, HR; Sun, XF; Tang, YL; Wan, WQ; Yang, LH; Yang, MH; Zheng, MC	1
Chen, L; Gong, S; Gulati, ES; Li, D; Liu, X; Wang, H; Wang, M; Xi, J; Xie, M; Zhang, H; Zhang, X	1
Huang, J; Shen, K; Yang, CL	1
Cai, X; Hu, G; Ni, X	1
Creutzig, U; Dworzak, M; Rasche, M; Reinhardt, D; von Neuhoff, N	1
Chen, Y; Deng, Y; Ding, B; He, Z; Ling, L; Shi, Y; Song, L; Tao, S; Wang, C; Yu, L	1
Anderson, J; Christ, TN; Churpek, JE; Curran, E; Godley, LA; Larson, RA; Liu, H; Odenike, T; Osman, AEG; Stock, W; Thirman, MJ	1
Jiang, W; Lee, SH	1
Autore, F; Bacigalupo, A; Chiusolo, P; Giammarco, S; Innocenti, I; Laurenti, L; Leone, G; Metafuni, E; Pagano, L; Piccirillo, N; Sica, S; Sorà, F	1
Batalini, F; Furtado, VF; Prilutskiy, A; Sloan, JM; Staziaki, PV	1
Breccia, M; Foà, R	1
Guffey, DJ; Teran, VA; Wilson, BB	1
Ahmad, Z; Aziz, SA; Baba, SM; Jan, A; Mir, KA; Pandith, AA; Shah, ZA	1
Adès, L; Avvisati, G; Burnett, AK; Chen, SJ; Döhner, H; Estey, EH; Fenaux, P; Iland, H; Kantarjian, H; Lengfelder, E; Lo-Coco, F; Löwenberg, B; Mathews, V; Montesinos, P; Naoe, T; Platzbecker, U; Ravandi, F; Rego, E; Russell, NH; Sanz, MA; Tallman, MS	1
Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Tsumura, Y; Yamada, Y	1
Huang, Y; Shao, S; Shi, P; Sun, Y; Wu, C; Zhao, S; Zhong, Q; Zhu, HH	1
Cao, P; Chen, X; Liu, H; Liu, M; Ma, X; Nie, D; Teng, W; Tian, Y; Wang, F; Wang, T; Wang, W; Zhang, J; Zhang, Y	1
Aster, JC; Avigan, D; Bhasin, MK; Cheloni, G; Chen, M; Clohessy, JG; Galinsky, I; Guarnerio, J; Lane, AA; Lee, JD; Lo-Coco, F; Longo, L; Mendez, L; Menon, AV; Monteleone, E; Mugoni, V; Pandolfi, PP; Panella, R; Pozdnyakova, O; Stone, RM; Stroopinsky, D; Zamora, JC	1
Fang, W; Hu, J; Sun, Q; Wang, Q	1
Aung, F; Borthakur, G; Chamoun, K; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, E; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, M; Naqvi, K; Ravandi, F; Wang, X; Yilmaz, M	1
Jin, J; Lou, Y; Mao, L; Tong, H; Wei, J; Xu, W; Yu, W	1
Chan, AM; Mascarenhas, J; Rhee, JY; Tallman, MS; Tremblay, D	1
Cruickshank, BM; Dean, CA; Holloway, RW; Hoskin, DW; Huynh, TT; Lee, K; Loung, CY; Marcato, P; Sultan, M; Vidovic, D; Waisman, DM; Weaver, ICG	1
Alfonso, V; Arcese, W; Baer, C; Cicconi, L; Del Principe, MI; Divona, M; Falconi, G; Ferrantini, A; Forghieri, F; Haferlach, T; Iaccarino, L; Lavorgna, S; Lo-Coco, F; Ottone, T; Travaglini, S; Usai, M; Venditti, A; Voso, MT	1
Batista, DA; Borowitz, MJ; Burns, KH; Duffield, AS; Gocke, CD; Miller, KP; Pratz, K; Venkataraman, G	1
De Simone, E; Di Micco, L; Mirenghi, F; Morelli, E	1
Agarwal, N; Bloom, L; Bregy, A; Gersey, Z; Komotar, RJ; Osiason, AD; Shah, S; Thompson, JW	1
Stahl, M; Tallman, MS	2
Chen, Y; Lai, BB; Mu, QT; Ouyang, GF; Zhang, YL	1
Albano, F; Amadori, S; Annibali, O; Avvisati, G; Borlenghi, E; Brandts, CH; Breccia, M; Brossart, P; Cairoli, R; Cicconi, L; Cortelezzi, A; Di Bona, E; Di Renzo, N; Divona, M; Dohner, H; Dohner, K; Efficace, F; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Fozza, C; Frairia, C; Ganser, A; Hanel, M; Hertenstein, B; La Nasa, G; Link, H; Lo-Coco, F; Lubbert, M; Mandelli, F; Maria D'Arco, A; Melillo, L; Paoloni, F; Platzbecker, U; Rambaldi, A; Rollig, C; Salih, HR; Sborgia, M; Schlenk, RF; Schmitz, N; Thiede, C; Vignetti, M; Voso, MT; Wattad, M	1
Bao, X; Hua, J; Xie, Y	1
Bachiasvili, K; Erba, HP; Mikhail, FM; Papadantonakis, N; Shah, G; Vachhani, P	1
Gunji, T; Hattori, D; Hosoba, R; Momoki, M; Nagao, R; Uryu, H; Yahagi, Y; Yamazaki, H	1
Chen, X; Feng, J; Hong, Y; Huang, Z; Wang, Y; You, X; Zheng, P	1
Eskazan, AE; Yilmaz, U	1
Bagheri, S	1
Hua, HU; Moshfeghi, AA; Rayess, N	1
Boissel, N; Brethon, B; Carausu, L; Ducassou, S; Gandemer, V; Garcia Spezza, E; Leverger, G; Mazingue, F; Petit, A; Reguerre, Y	1
Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL	1
Gao, X; Huang, H; Liu, J; Mou, S; Shen, L; Yin, T; Ying, L	1
Cho, BS; Cho, SG; Eom, KS; Jeon, YW; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, GJ; Park, S; Park, SS; Shin, SH; Yahng, SA; Yoon, JH	1
Breccia, M; Cordoba, R; Hamaker, ME; Klepin, HD; Larson, RA; Montesinos, P; Neuendorff, NR	1
Chan, SY; Dang, CC; Guan, YK; Lau, NS	1
Appelbaum, FR; Coutre, SE; DeAngelo, DJ; Erba, HP; Komrokji, RS; Lancet, JE; Litzow, MR; Moseley, AB; Othus, M; Tallman, MS	1
Fujita, H; Ishikawa, Y; Yokoyama, Y	1
Farmer, I; Gupta, S; Kulasekararaj, AG; Littlewood, S; Moonim, M; Okikiolu, J; Oram, SH; Steel, M; Thanigaikumar, M; Wanniarachchi, C; Yeghen, T	1
Hashmi, H; Nishihori, T	1
Fan, Z; Huang, DP; Huang, LB; Li, Y; Liang, C; Luo, XQ; Peng, CJ; Tang, WY; Tang, YL; Wang, LN; Zhang, XL; Zheng, LM	1
Annibali, O; Borlenghi, E; Breccia, M; Cottone, F; Efficace, F; Luppi, M; Rodeghiero, F; Vignetti, M	1
Naoe, T	1
Chaudhry, S; Gupta, DK; Jain, A; Khosla, H; Nagpal, K; Prasad, P; Saluja, S; Sharma, M; Tatawadiya, S	1
Ji, L; Jiang, Y	1
Ge, Z; Gu, S; Ma, J; Zi, J	1
Baron, J; Freyer, CW; Luger, SM; Man, Y; Peterson, CE; Przespolewski, A	1
He, J; Wang, L; Yan, X	1
Yokoyama, Y	1
Feng, H; He, P; Li, M; Wang, H; Wang, W; Wang, X; Zhao, J; Zheng, X; Zhu, H	1
Fakhimahmadi, A; Ghavamzadeh, A; Haghi, A; Mohammadi Kian, M; Mohammadi, S; Moosavi, MA; Nikbakht, M; Rahmati, M; Salemi, M; Yousefi, H	1
Breccia, M	1
Fukuda, K; Iimura, Y; Isshiki, T; Nagasawa, T; Sato, Y; Suzuki, S; Yoshizawa, Y	1
Gang, EJ; Le, J; Li, SY; Liu, HC; Lu, Y; Pei, RZ; Qian, SY; Si, T; Tang, SH	1
Buhtoiarov, IN	1
de Botton, S; DiNardo, CD; Fathi, AT; Levis, MJ; Montesinos, P; Stein, EM	1
Chen, S; Han, Y; Hu, X; Ke, P; Li, C; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D; Wu, Y; Zhou, H	1
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA	1
Bai, Y; Dou, L; Li, D; Niu, J; Niu, X; Qin, L; Sun, K; Wei, S; Xiao, M; Zhang, L; Zhang, W; Zhou, P	1
Pemmaraju, N	1
Haghighat, S; Mokhtari, M; Rezvani, A	1
Bhattacharyya, P; Gehani, A; Ghara, N; Ghosh, P; Sarkar, S	1
Annibali, O; Arcese, W; Castelli, R; Cicconi, L; Cristiano, A; Della Porta, M; Divona, M; Esteve, J; Fabiani, E; Falconi, G; Lazarevic, V; Lo-Coco, F; Montesinos, P; Nardozza, AM; Ottone, T; Rego, E; Rossi, M; Testi, AM; Venditti, A; Voso, MT	1
Abraham, J; Adès, L; Aljijakli, A; Arar, A; Aulitzky, WE; Baldus, CD; Berceanu, A; Berthon, C; Bonmati, C; Bornhäuser, M; Braun, T; Carassou, P; Carre, M; Chermat, F; De Wit, M; Fenaux, P; Gnadler, M; Görner, M; Götze, KS; Haiat, S; Hicheri, Y; Hiddemann, W; Jost, E; Kayser, S; Keller, U; Krämer, A; Krause, SW; Kunzmann, V; Lebon, D; Lengfelder, E; Müller-Tidow, C; Niemann, D; Noppeney, R; Orvain, C; Peterlin, P; Platzbecker, U; Raffoux, E; Rahme, R; Reichle, A; Rigaudeau, S; Röllig, C; Saillard, C; Schäfer-Eckart, K; Schlenk, RF; Schwänen, C; Serve, H; Spiekermann, K; Stölzel, F; Thiede, C; Wemeau, M; Willekens, C	1
Levis, M	1
Alves, VM; Brassesco, MS; Fugio, LB; Garcia, CB; Goto, RN; Greene, LJ; Leopoldino, AM; Padovani, KS; Rego, EM	1
Chen, Y; Dai, Y; Fang, Y; Feng, X; Gao, H; Han, Y; Hao, G; He, Z; Hu, Q; Hu, S; Jiang, H; Jin, R; Ju, X; Li, F; Li, J; Li, L; Liang, H; Liao, N; Lin, L; Ling, Y; Liu, A; Liu, W; Luo, J; Luo, X; Pan, K; Peng, X; Peng, Y; Qu, L; Shen, D; Sun, L; Tao, Y; Tian, X; Wang, L; Wang, N; Wang, T; Xiao, P; Yan, M; Yin, Q; Zhai, X; Zhang, J; Zhang, R; Zhang, Y; Zheng, H; Zhou, M; Zhu, J	1
Breccia, M; Cannella, L; Efficace, F; Olivieri, J; Platzbecker, U; Vignetti, M	1
Baer, MR; DeZern, A; Duong, VH; Emadi, A; Gehrie, E; Ghiaur, G; Gojo, I; Hambley, B; Hickey, E; Kashanian, S; Levis, MJ; Li, A; Newman, MJ; Smith, BD; Varadhan, R; Zacholski, K	1
Arena, V; Diverio, D; Foà, R; Ladogana, S; Lo Nigro, L; Locatelli, F; Masetti, R; Menna, G; Micalizzi, C; Micheletti, MV; Mohamed, S; Onofrillo, D; Piciocchi, A; Pierani, P; Putti, C; Rizzari, C; Santoro, N; Testi, AM; Timeus, F; Zecca, M; Ziino, O	1
Su, YZ; Tao, HF; Xu, LW	1
Kantarjian, H; Ravandi, F; Yilmaz, M	1
Au, WY; Cheuk, D; Chu, HT; Gill, H; Ha, SY; Kumana, CR; Kwong, YL; Lee, E; Lee, P; Leung, RYY; Ma, ESK; Yim, R; Yip, PK; Yung, Y	1
Chang, YJ; Gong, LZ; Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Liu, XH; Lu, SY; Qin, YZ; Shi, HX; Tang, FF; Wang, J; Zhao, T; Zhao, XS	1
Micieli, JA; Paxton, AB	1
Costa, LJ; Dhir, A; Jamy, OH; Xavier, AC	1
Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; David, S; Ganesan, S; Janet, NB; Korula, A; Krishna, S; Kulkarni, U; Kumar, SP; Mathews, V; Palani, HK; Radhakrishnan, NR; Venkatraman, A; Yasar, M	1
Allen, S; Budman, D; Calabro, A; Devoe, C; Dhingra, R; Ghiuzeli, CM; Saunders, J; Stýblo, M	1
Ammatuna, E; Diepstra, A; Hazenberg, CLE; Huls, GA; Santing, M	1
Abla, O; Alonzo, TA; Feusner, JH; Gamis, AS; Gerbing, RB; Gregory, J; Hardy, KK; Hardy, S; Hirsch, BA; Kahwash, S; Kolb, EA; Kutny, MA; Meshinchi, S; Raimondi, S; Rajpurkar, M; Wang, YC	1
Li, Y; Xu, Q; Yu, J; Zhang, K	1
Hayakawa, A; Horibe, K; Iijima-Yamashita, Y; Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yamada, Y	1
Abraham, A; Arunachalam, AK; Balasubramanian, P; Balasundaram, N; Devasia, AJ; Fouzia, NA; George, B; Janet, NB; Korula, A; Kulkarni, UP; Lakshmanan, J; Lionel, S; Mani, T; Mathews, V; Nair, SC; Palani, HK; Prakash, MA; Selvarajan, S; Venkataraman, A	1
Jin, J; Naranmandura, H; Wang, HF; Wang, QQ; Zhao, JZ; Zhu, HH	1
Chen, X; Yu, D; Yu, Q	1
Mao, Y; Tang, F; Xu, X; Zhu, X	1
Chen, Y; Feng, C; Li, C; Li, P; Li, Y; Peng, X; Wang, Z; Wu, P; Xiong, X	1
Fang, S; Shi, J; Wang, C; Wang, Y; Yang, H; Zuo, N	1
Chahardouli, B; Hoseinzadeh, G; Moghaddam, KA; Mohammadzadeh, Z; Mousavi, SA; Omidkhoda, A; Rostami, S	1
Chen, YQ; Huang, DP; Huang, LB; Li, Y; Liang, C; Liao, LH; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wang, LN; Yang, LH; Ye, ZL; Zhang, XL	1
Ahn, MJ; Bae, SH; Bang, SM; Cho, EK; Choi, JH; Chong, SY; Hyun, MS; Jo, DY; Kim, B; Kim, BS; Kim, CS; Kim, DY; Kim, H; Kim, HJ; Kim, HS; Kim, I; Kim, SH; Kwon, H; Lee, JH; Lee, KH; Lee, MH; Lee, WS; Min, YJ; Moon, HN; Mun, YC; Nam, SH; Oh, D; Park, JH; Park, KT; Park, SY; Park, YH; Ryoo, HM; Seo, JJ; Seong, CM; Yoon, HJ; Yoon, SS; Zang, DY	1
Yanada, M	1
Herold, T; Hiddemann, W; Rausch, C; Spiekermann, K; von Bergwelt-Baildon, M	1
Korsos, V; Miller, WH	1
Chen, Y; Wang, J; Wu, W; Xue, X; Zheng, N	1
Chen, K; Chen, W; Clode, P; Guagliardo, P; Huang, S; Jiang, H; Leung, JK; Song, W; Xu, J; Young, SG	1
Bunce, CM; Drayson, MT; Khanim, FL	1
Hussain, L; Kang, YY; Ma, YF; Maimaitiyiming, Y; Naranmandura, H; Wang, QQ; Wang, SC; Yang, C; Yang, T; Yu, PH; Yu, WJ; Zhu, CY	1
Bai, LH; Jiang, YF; Li, J; Li, RJ; Peng, HL; Shen, JK; Yan, WZ	1
Chen, SN; Huang, J; Jin, J; Li, L; Li, ZY; Lou, LJ; Lou, YJ; Lu, Y; Ma, YF; Mao, LP; Meng, HT; Qian, JJ; Sun, CH; Wang, HY; Wei, JY; Wu, Q; Xu, GX; Xu, JY; Yan, XY; Yang, M; Yu, WJ; Zhu, HH; Zhu, XL	1
Wiernik, PH	1
Chen, LM; Gong, S; He, PC; Li, GH; Liu, HB; Liu, L; Lu, XH; Qin, WW; Wald, DN; Wang, HY; Wang, MC; Wei, SH; Xi, JY; Yao, YZ; Zhang, CS; Zhang, HY; Zhang, M; Zhang, XX; Zheng, YS; Zhu, HH	1
Cui, X; He, C; Huang, J; Jia, Y; Li, H; Li, J; Liu, Z; Ma, H; Niu, T; Tang, Y; Wu, Y; Xiang, B; Xie, L	1
Das, C; Das, R; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U	1
He, J; Li, W; Lu, D; Lu, P; Shi, Y; Su, Y; Wu, S; Yang, J; Zhang, G; Zhang, M; Zhang, X	1
Duan, X; Liu, B; Yang, M	1
Ball, ED; Borthakur, G; Cai, Z; Chen, SN; Chu, XX; Du, X; Gao, SJ; Hao, JP; Hu, J; Huang, JY; Huang, RB; Jin, J; Kantarjian, HM; Li, J; Li, JH; Liu, HX; Liu, LP; Liu, YJ; Lu, Y; Luo, H; MacMahon, S; Mi, YC; Qin, YZ; Sanz, MA; Shen, SH; Su, Z; Such, E; Taussig, DC; Wang, HY; Wang, W; Wang, Y; Welch, JS; Wen, LJ; Xu, R; Yan, XJ; Yin, CC; You, MJ; Yu, L; Yu, YF; Yuan, HJ; Zhang, C; Zhang, JY; Zhang, LP; Zhang, XY; Zhang, ZL; Zhou, HS; Zhu, HH	1
Dai, B; Gao, W; Hu, J; Li, J; Li, K; Li, Y; Wang, F; Wang, L; Wang, Y; Zhang, T; Zhao, L; Zhu, H; Zhu, J	1
Borges, GSM; de Mello Gomides Loures, C; de Paula Sabino, A; Evangelista, FGC; Fernandes, C; Ferreira, LAM; Richard, S; Sales, CC; Sicard, P	1
Benoit, TM; Gundermann, S	1
Balajthy, Z; Botó, P; Czimmerer, Z; Fésüs, L; Jambrovics, K; Kolostyák, Z; Pap, A; Sarang, Z; Szatmari, I; Uray, IP	1
Cao, P; Chen, J; Chen, X; Fang, J; Li, H; Li, L; Liu, H; Liu, M; Ma, X; Wang, F; Wu, H; Yuan, L; Zhang, Y; Zhao, Z; Zhou, X	1
Bajel, A; Blombery, PA; Chan, KL; Dun, K; Nedumannil, R; Ng Liet Hing, M; Nguyen, T; Ninkovic, S; Ryland, GL; Tiong, IS; Westerman, DA	1
Chen, J; Chen, S; Luo, H; Wang, S; Wu, W	1
Abraham, A; Balasubramanian, P; Fouzia, NA; George, B; Kulkarni, UP; Lionel, S; Mani, T; Mathews, V; Nair, SC; Selvarajan, S	1
Acconcia, F; Albanesi, J; Bianchi, F; di Masi, A; Franza, M; Leone, S; Mancini, B; Pennisi, R	1
Balajthy, Z; Jambrovics, K; Póliska, S; Scholtz, B; Uray, IP	1
Amirzargar, MR; Faranoush, M; Kooshari, A; Nekouian, R; Shahidi, M; Shahriyary, F; Vafajoo, M	1
Bachiashvili, K; Bathini, S; Bhatia, R; Choi, JK; Dunn-Valadez, S; Godby, K; Goyal, G; Jamy, O; Mehta, A; Mikhail, FM; Morlote, D; Oliver, JD; Purdy, KE; Rangaraju, S; Reddy, VB; Vachhani, P; Worth, S	1
Ahluwalia, J; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, N; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U	1
Chen, GH; Chen, HQ; Chen, YQ; Fan, Z; Feng, XQ; Guo, BY; Huang, DP; Huang, LB; Lan, HK; Li, B; Li, WL; Li, Y; Liang, C; Liu, RY; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wan, WQ; Wang, LN; Yang, LC; Yang, LH; Zhang, XL; Zhen, ZJ; Zhou, DH	1

Reviews

135 review(s) available for arsenic trioxide and tretinoin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine]. Nederlands tijdschrift voor geneeskunde, 1999, Aug-21, Volume: 143, Issue:34 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	1999
[Recent advances of differentiation-inducing therapy for leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:3 Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Histone Deacetylase Inhibitors; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Transcription, Genetic; Tretinoin	2000
Arsenicals and inhibitors of histone deacetylase as anticancer therapy. Haematologica, 1999, Volume: 84 Suppl EHA-4 Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin	1999
Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia. Current oncology reports, 2000, Volume: 2, Issue:6 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Disease Models, Animal; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2000
Acute progranulocytic leukemia. Current opinion in oncology, 2001, Volume: 13, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Prognosis; Salvage Therapy; Survival Analysis; Tretinoin	2001
Histone deacetylases and transcriptional therapy with their inhibitors. Cancer chemotherapy and pharmacology, 2001, Volume: 48 Suppl 1 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mice; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription, Genetic; Tretinoin	2001
APL, a model disease for cancer therapies? Oncogene, 2001, Oct-29, Volume: 20, Issue:49 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; Cellular Senescence; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Multigene Family; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin	2001
Arsenic trioxide, a therapeutic agent for APL. Oncogene, 2001, Oct-29, Volume: 20, Issue:49 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease Models, Animal; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Remission Induction; Survival Rate; Transcription Factors; Tretinoin; Tumor Suppressor Proteins	2001
Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene, 2001, Oct-29, Volume: 20, Issue:49 Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Caspases; Cell Differentiation; Cysteine Endopeptidases; Humans; Leukemia, Promyelocytic, Acute; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Remission Induction; Tretinoin	2001
Acute promyelocytic leukemia: evolving therapeutic strategies. Blood, 2002, Feb-01, Volume: 99, Issue:3 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Tretinoin	2002
Advances in the treatment of relapsed acute promyelocytic leukemia. Acta haematologica, 2002, Volume: 107, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Recurrence; Tretinoin	2002
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. The oncologist, 2002, Volume: 7 Suppl 1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin	2002
Introduction. Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Tretinoin	2002
Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia. Leukemia & lymphoma, 2002, Volume: 43, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Drug Carriers; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Liposomes; Oxides; Tretinoin	2002
Management of acute promyelocytic leukemia. Current oncology reports, 2002, Volume: 4, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin	2002
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. The oncologist, 2003, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Combined Modality Therapy; Europe; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Regression, Spontaneous; Oxides; Practice Guidelines as Topic; Risk Factors; Tretinoin; United States	2003
Targeted therapies for the treatment of leukemia. Seminars in oncology nursing, 2003, Volume: 19, Issue:2 Topics: Alemtuzumab; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Dose-Response Relationship, Drug; Drug Interactions; Gemtuzumab; Humans; Imatinib Mesylate; Leukemia; Nurse-Patient Relations; Nurse's Role; Oncology Nursing; Oxides; Patient Education as Topic; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Tretinoin	2003
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia]. Orvosi hetilap, 2003, Sep-07, Volume: 144, Issue:36 Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin	2003
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:12 Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil	2003
The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia. Leukemia & lymphoma, 2004, Volume: 45, Issue:4 Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin	2004
Acute promyelocytic leukemia as a paradigm for targeted therapy. Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 4 Topics: Arsenic Trioxide; Arsenicals; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2004
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematological oncology, 2004, Volume: 22, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin	2004
Arsenic trioxide in the treatment of haematological malignancies. Expert opinion on drug safety, 2004, Volume: 3, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Oxides; Remission Induction; Salvage Therapy; Tretinoin	2004
Acute promyelocytic leukemia: a model of molecular target based therapy. Hematology (Amsterdam, Netherlands), 2005, Volume: 10 Suppl 1 Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2005
Treatment concepts of acute promyelocytic leukemia. Critical reviews in oncology/hematology, 2005, Volume: 56, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin	2005
Strategies for the treatment of acute promyelocytic leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2006, Volume: 4, Issue:1 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2006
[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:8 Topics: Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin	2006
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert review of anticancer therapy, 2006, Volume: 6, Issue:9 Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiovascular Diseases; Heart Diseases; Humans; Interferons; Interleukin-2; Neoplasms; Oxides; Stilbenes; Tretinoin	2006
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leukemia & lymphoma, 2006, Volume: 47, Issue:11 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Tretinoin	2006
The design of selective and non-selective combination therapy for acute promyelocytic leukemia. Current topics in microbiology and immunology, 2007, Volume: 313 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2007
Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide. Cellular & molecular immunology, 2006, Volume: 3, Issue:6 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytokines; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Tretinoin	2006
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2007, Jun-29, Volume: 362, Issue:1482 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2007
Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. The international journal of biochemistry & cell biology, 2007, Volume: 39, Issue:6 Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Tretinoin	2007
Targeting transcription factors in acute leukemia in children. Current drug targets, 2007, Volume: 8, Issue:6 Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; DNA Methylation; Drug Delivery Systems; Histone Deacetylase Inhibitors; Humans; Leukemia; Oxides; Transcription Factors; Tretinoin	2007
Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation. Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cranial Irradiation; Daunorubicin; Ear Neoplasms; Humans; Injections, Spinal; Leukemia, Myelomonocytic, Acute; Male; Oxides; Radiography; Remission Induction; Sarcoma, Myeloid; Tretinoin	2007
Leukemia, an effective model for chemical biology and target therapy. Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin	2007
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era. Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Disease Models, Animal; Humans; Imatinib Mesylate; Leukemia; Oxides; Piperazines; Pyrimidines; Tretinoin	2007
PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia. International journal of clinical oncology, 2007, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tetrahydronaphthalenes; Tretinoin	2007
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, Mar-01, Volume: 111, Issue:5 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2008
The expanding role of arsenic in acute promyelocytic leukemia. Seminars in hematology, 2008, Volume: 45, Issue:3 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2008
[Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment]. Postepy higieny i medycyny doswiadczalnej (Online), 2008, Sep-09, Volume: 62 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Drug Therapy, Combination; Glutathione; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Neoplasms; NF-kappa B; Oxides; Tretinoin	2008
What is the role of arsenic in newly diagnosed APL? Best practice & research. Clinical haematology, 2008, Volume: 21, Issue:4 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2008
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology. American Society of Hematology. Education Program, 2008 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Chromosome Aberrations; Genetic Markers; Humans; Karyotyping; Leukemia, Myeloid, Acute; Models, Genetic; Mutation; Oxides; Proto-Oncogene Proteins c-kit; Transcription, Genetic; Tretinoin	2008
Transcriptome and proteome analyses of drug interactions with natural products. Current drug metabolism, 2008, Volume: 9, Issue:10 Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin	2008
Differentiation therapy of acute myeloid leukemia: past, present and future. Current opinion in hematology, 2009, Volume: 16, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Sensitivity and Specificity; Tretinoin	2009
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system. CNS & neurological disorders drug targets, 2009, Volume: 8, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Central Nervous System Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin	2009
Acute promyelocytic leukemia in childhood. Current oncology reports, 2009, Volume: 11, Issue:6 Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Translocation, Genetic; Tretinoin	2009
[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2009, Volume: 7, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin	2009
Acute promyelocytic leukemia: what are the treatment options? Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:4 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Tretinoin	2010
Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer treatment and research, 2010, Volume: 145 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dyspnea; Fever; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Models, Biological; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Treatment Outcome; Tretinoin	2010
The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia. Current stem cell research & therapy, 2010, Volume: 5, Issue:4 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cell Transformation, Neoplastic; Glutamates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Myeloid Progenitor Cells; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Prodrugs; Promyelocytic Leukemia Protein; Transcription Factors; Tretinoin; Tumor Suppressor Proteins	2010
Modern approaches to treating acute promyelocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-10, Volume: 29, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2011
Differentiation syndrome in patients with acute promyelocytic leukemia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Glucocorticoids; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Oxides; Risk Factors; Syndrome; Time Factors; Tretinoin	2012
The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult	2011
Advances in therapies for acute promyelocytic leukemia. Cancer science, 2011, Volume: 102, Issue:11 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Risk; Salvage Therapy; Tretinoin	2011
[All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2011, Volume: 52, Issue:7 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin	2011
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2011
Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. Oncology (Williston Park, N.Y.), 2011, Volume: 25, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2011
Current treatment strategy of acute promyelocytic leukemia. Frontiers of medicine, 2011, Volume: 5, Issue:4 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Secondary Prevention; Survival Rate; Tretinoin	2011
Pathogenesis and treatment of leukemia: an Asian perspective. Expert opinion on therapeutic targets, 2012, Volume: 16 Suppl 1 Topics: Arsenic Trioxide; Arsenicals; Asian People; Cell Proliferation; Humans; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin	2012
[Current treatment of acute myeloid leukaemia in adults]. Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7 Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin	2012
How to manage acute promyelocytic leukemia. Leukemia, 2012, Volume: 26, Issue:8 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; Consolidation Chemotherapy; Drug Synergism; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Recurrence; Tretinoin	2012
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:7 Topics: Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin	2012
Bleeding and thrombosis in acute promyelocytic leukemia. American journal of hematology, 2012, Volume: 87, Issue:6 Topics: Antifibrinolytic Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Clinical Trials as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Disseminated Intravascular Coagulation; Factor VIIa; Factor VIII; Fibrinogen; Fibrinolysis; Hemorrhage; Heparin; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Plasma; Platelet Count; Platelet Transfusion; Recombinant Proteins; Thromboplastin; Thrombosis; Treatment Failure; Tretinoin	2012
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond. IUBMB life, 2012, Volume: 64, Issue:8 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Core Binding Factor Alpha 2 Subunit; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured	2012
Provocative pearls in diagnosing and treating acute promyelocytic leukemia. Oncology (Williston Park, N.Y.), 2012, Volume: 26, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Biopsy, Fine-Needle; Bone Marrow; Clinical Trials as Topic; Dexamethasone; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Prognosis; Pulmonary Edema; Remission Induction; Respiratory Insufficiency; Tretinoin	2012
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia. International journal of hematology, 2013, Volume: 97, Issue:6 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin	2013
Management of elderly patients with acute promyelocytic leukemia: progress and problems. Annals of hematology, 2013, Volume: 92, Issue:9 Topics: Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2013
Acute promyelocytic leukemia: do we have a new front-line standard of treatment? Current oncology reports, 2013, Volume: 15, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Remission Induction; Tretinoin	2013
Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia. Hematology (Amsterdam, Netherlands), 2014, Volume: 19, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin	2014
Biology and management of therapy-related acute promyelocytic leukemia. Current opinion in oncology, 2013, Volume: 25, Issue:6 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Early Diagnosis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Retrospective Studies; Risk Factors; Tretinoin	2013
Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, 2013, Dec-01, Volume: 11, Issue:12 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Monitoring, Physiologic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Tretinoin	2013
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. The Journal of experimental medicine, 2013, Dec-16, Volume: 210, Issue:13 Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Remission Induction; Signal Transduction; Transcriptional Activation; Tretinoin	2013
[Acute promyelocytic leukemia--modern approach to disease pathogenesis and differentiation treatment]. Postepy higieny i medycyny doswiadczalnej (Online), 2013, Nov-25, Volume: 67 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Secondary Prevention; Survival Rate; Tretinoin	2013
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia? Current opinion in hematology, 2014, Volume: 21, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Standard of Care; Treatment Outcome; Tretinoin	2014
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood, 2014, May-01, Volume: 123, Issue:18 Topics: Adult; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Premedication; Syndrome; Tretinoin	2014
Contemporary treatment of APL. Current hematologic malignancy reports, 2014, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin	2014
What is the standard regimen for patients with acute promyelocytic leukemia? Current hematologic malignancy reports, 2014, Volume: 9, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Practice Guidelines as Topic; Tretinoin	2014
Advanced progress on the relationship between RA and its receptors and malignant tumors. Critical reviews in oncology/hematology, 2014, Volume: 91, Issue:3 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Neoplastic Cells, Circulating; Oxides; Receptors, Retinoic Acid; Signal Transduction; Tretinoin	2014
Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Disease Models, Animal; DNA End-Joining Repair; Drug Synergism; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin	2014
The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years. Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Annexin A2; Anticoagulants; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Coagulation Tests; Carboxypeptidase B2; Disseminated Intravascular Coagulation; Fibrinolysis; Forecasting; Granulocyte Precursor Cells; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Risk Factors; S100 Proteins; Thrombomodulin; Thrombophilia; Thromboplastin; Tretinoin; Urokinase-Type Plasminogen Activator	2014
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide. Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Anthracyclines; Antibiotics, Antineoplastic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Topoisomerase II Inhibitors; Transcription, Genetic; Tretinoin	2014
Conventional induction and post-remission therapy in APL: have we arrived? Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin	2014
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care. Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin	2014
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia? Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Differentiation; Clinical Trials as Topic; Disease Management; Drug Monitoring; Drug Resistance, Neoplasm; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Real-Time Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Tretinoin	2014
Extramedullary disease in APL: a real phenomenon to contend with or not? Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cerebral Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Models, Biological; Multicenter Studies as Topic; Organ Specificity; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Tetrahydronaphthalenes; Tretinoin	2014
Treatment of paediatric APL: how does the therapeutic approach differ from adults? Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:1 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin	2014
Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction. International journal of hematology, 2014, Volume: 100, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Tretinoin	2014
Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies. British journal of cancer, 2015, Feb-03, Volume: 112, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Treatment Outcome; Tretinoin	2015
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Oct-01, Volume: 20, Issue:19 Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Management; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Tretinoin	2014
[Treatment for acute promyelocytic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disseminated Intravascular Coagulation; Gene Fusion; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Molecular Targeted Therapy; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Suppressor Proteins	2014
Molecular mechanisms of the antileukemia activities of retinoid and arsenic. Journal of pharmacological sciences, 2014, Volume: 126, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin	2014
Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood cancer journal, 2015, Apr-17, Volume: 5 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Failure; Tretinoin	2015
Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis. Acta haematologica, 2015, Volume: 134, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Risk; Tretinoin	2015
Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. Journal of internal medicine, 2015, Volume: 278, Issue:6 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Translational Research, Biomedical; Tretinoin	2015
[Pathogenesis of Acute Promyelocytic Leukemia]. Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:5 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Epigenomics; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Tretinoin	2015
p53 as an Effector or Inhibitor of Therapy Response. Cold Spring Harbor perspectives in medicine, 2015, Dec-04, Volume: 6, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Tumor Suppressor Protein p53	2015
Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Epigenesis, Genetic; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Medical Oncology; Molecular Medicine; Mutation; Oxides; ras Proteins; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Tretinoin	2015
Current standard treatment of adult acute promyelocytic leukaemia. British journal of haematology, 2016, Volume: 172, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Early Diagnosis; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin	2016
Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:11 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Disease Progression; Fatal Outcome; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Isochromosomes; Karyotype; Leukemia, Promyelocytic, Acute; Male; Molecular Diagnostic Techniques; Mutation; Oncogene Proteins, Fusion; Oxides; Phenotype; Predictive Value of Tests; Time Factors; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult	2015
Optimal treatment strategies for high-risk acute promyelocytic leukemia. Current opinion in hematology, 2016, Volume: 23, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin	2016
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Disseminated Intravascular Coagulation; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Hemorrhagic Disorders; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocyte Count; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Risk Factors; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Tumor Protein p73; Tumor Suppressor Proteins	2016
Current management of newly diagnosed acute promyelocytic leukemia. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin	2016
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis. PloS one, 2016, Volume: 11, Issue:7 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2016
Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid. Archives of gynecology and obstetrics, 2018, Volume: 297, Issue:2 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gestational Age; Humans; Leukemia, Promyelocytic, Acute; Neoadjuvant Therapy; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Tretinoin	2018
Differentiation therapy revisited. Nature reviews. Cancer, 2018, Volume: 18, Issue:2 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2018
[Acute promyelocytic leukaemia]. Ugeskrift for laeger, 2018, 01-15, Volume: 180, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disseminated Intravascular Coagulation; History, 20th Century; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Tretinoin	2018
Management of patients with acute promyelocytic leukemia. Leukemia, 2018, Volume: 32, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Electrocardiography; Female; Fetus; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasms, Second Primary; Pregnancy; Recurrence; Renal Dialysis; Renal Insufficiency; Tretinoin	2018
The success and the challenge of all-trans retinoic acid in the treatment of cancer. Critical reviews in food science and nutrition, 2019, Volume: 59, Issue:sup1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Proliferation; Drug Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Receptors, Retinoic Acid; Signal Transduction; Tretinoin	2019
[Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations]. Klinische Padiatrie, 2018, Volume: 230, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Humans; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin	2018
Treatment of Acute Promyelocytic Leukemia in Adults. Journal of oncology practice, 2018, Volume: 14, Issue:11 Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Central Nervous System Neoplasms; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Drug Administration Schedule; Expert Testimony; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Neoplasm Grading; Neoplasm Staging; Tretinoin	2018
Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. Expert review of hematology, 2019, Volume: 12, Issue:2 Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin	2019
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 04-11, Volume: 133, Issue:15 Topics: Aged; Arsenic Trioxide; Disease Management; Female; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Practice Guidelines as Topic; Pregnancy; Recurrence; Tretinoin	2019
Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review. Blood advances, 2019, 06-25, Volume: 3, Issue:12 Topics: Aged; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Drug Therapy, Combination; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Myoclonus; Remission Induction; Steroids; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin; Withholding Treatment	2019
Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme. World neurosurgery, 2019, Volume: 131 Topics: ADAM Proteins; Amyloid Precursor Protein Secretases; Antineoplastic Agents; Arsenic Trioxide; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Gene Knockdown Techniques; Glioblastoma; Humans; Inhibitor of Differentiation Proteins; Kruppel-Like Transcription Factors; MicroRNAs; Microvessels; Molecular Targeted Therapy; Neoplasm Proteins; Netrin-1; Niclosamide; Receptors, Notch; Receptors, Urokinase Plasminogen Activator; Resveratrol; Signal Transduction; Tretinoin	2019
Differentiation syndrome in acute promyelocytic leukaemia. British journal of haematology, 2019, Volume: 187, Issue:2 Topics: Acute Kidney Injury; Arsenic Trioxide; Cell Differentiation; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Pulmonary Edema; Steroids; Syndrome; Tretinoin	2019
Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leukemia & lymphoma, 2019, Volume: 60, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Mortality; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Time Factors; Tretinoin	2019
Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. Journal of geriatric oncology, 2020, Volume: 11, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Remission Induction; Treatment Outcome; Tretinoin	2020
Role of hematopoietic cell transplantation in relapsed acute promyelocytic leukemia. Clinical transplantation, 2020, Volume: 34, Issue:9 Topics: Arsenic Trioxide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Transplantation, Autologous; Treatment Outcome; Tretinoin	2020
＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement. Nagoya journal of medical science, 2020, Volume: 82, Issue:2 Topics: Aged; Aged, 80 and over; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Decitabine; fms-Like Tyrosine Kinase 3; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Smoothened Receptor; Staurosporine; Sulfonamides; Survival Rate; Tretinoin; Triazines	2020
Cryptic t(15;17) acute promyelocytic leukemia with a karyotype of add(11)(p15) and t(13,20)- A case report with a literature review. Bosnian journal of basic medical sciences, 2021, Apr-01, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Tretinoin	2021
Does acute promyelocytic leukemia patient with the STAT5B/RARa fusion gene respond well to decitabine?: A case report and literature review. Medicine, 2020, Oct-23, Volume: 99, Issue:43 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Asian People; Consolidation Chemotherapy; Cytarabine; Decitabine; Drug Therapy, Combination; Female; Hospitalization; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Treatment Outcome; Tretinoin	2020
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. American journal of hematology, 2021, 06-01, Volume: 96, Issue:6 Topics: Acute Kidney Injury; Adrenal Cortex Hormones; Antineoplastic Agents; Arsenic Trioxide; Cell Differentiation; Clinical Trials as Topic; Cytokine Release Syndrome; Edema; Enzyme Inhibitors; Epigenesis, Genetic; Fever; fms-Like Tyrosine Kinase 3; Humans; Hypotension; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelopoiesis; Neoplasm Proteins; Pleural Effusion; Respiration Disorders; Tretinoin	2021
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 2021, 04-15, Volume: 127, Issue:8 Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine	2021
Acute promyelocytic leukemia with myelofibrosis: A case report and literature review. Medicine, 2021, Apr-02, Volume: 100, Issue:13 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Primary Myelofibrosis; Treatment Outcome; Tretinoin	2021
Successful treatment of acute promyelocytic leukemia in a patient with prosthetic heart valves: a case report and review of the literature. Journal of medical case reports, 2021, May-04, Volume: 15, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Heart Valves; Heparin; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin	2021
Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review. Expert review of hematology, 2021, Volume: 14, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Quality of Life; Treatment Outcome; Tretinoin	2021
Acute promyelocytic leukemia current treatment algorithms. Blood cancer journal, 2021, 06-30, Volume: 11, Issue:6 Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Tretinoin	2021
Treatment for relapsed acute promyelocytic leukemia. Annals of hematology, 2022, Volume: 101, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin	2022
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy. Journal of molecular endocrinology, 2022, 11-01, Volume: 69, Issue:4 Topics: Arsenic; Arsenic Trioxide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins	2022
Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies. Pharmacological research, 2022, Volume: 184 Topics: Antineoplastic Agents; Arsenic Trioxide; beta Catenin; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; NF-kappa B; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Tretinoin	2022
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies. Blood cancer journal, 2022, 10-07, Volume: 12, Issue:10 Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin	2022
Refractory acute promyelocytic leukemia with PLZF/RARa rearrangement: a case report and literature review. Anti-cancer drugs, 2023, 06-01, Volume: 34, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2023
The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials. Journal of ethnopharmacology, 2023, Nov-15, Volume: 316 Topics: Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Randomized Controlled Trials as Topic; Tretinoin	2023

Trials

48 trial(s) available for arsenic trioxide and tretinoin

Article	Year
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia, 1999, Volume: 13, Issue:7 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Daunorubicin; Drug Screening Assays, Antitumor; Endothelium, Vascular; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin	1999
Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution. International journal of hematology, 1999, Volume: 70, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Tretinoin	1999
[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid]. Zhonghua nei ke za zhi, 1999, Volume: 38, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin	1999
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-15, Volume: 21, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Tretinoin	2003
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood, 2003, Jul-01, Volume: 102, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin	2003
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2004, Apr-13, Volume: 101, Issue:15 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prospective Studies; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin; Tumor Cells, Cultured	2004
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 2006, May-01, Volume: 107, Issue:9 Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Tretinoin	2006
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials). Leukemia, 2006, Volume: 20, Issue:5 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Europe; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence; Risk Factors; Treatment Outcome; Tretinoin	2006
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients. Leukemia research, 2008, Volume: 32, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Risk Factors; Thalidomide; Treatment Outcome; Tretinoin	2008
Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta haematologica, 2009, Volume: 121, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Rate; Time Factors; Tretinoin	2009
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-20, Volume: 28, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Young Adult	2010
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood, 2010, Nov-11, Volume: 116, Issue:19 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; North America; Oxides; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult	2010
Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China. International journal of hematology, 2011, Volume: 93, Issue:2 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; China; Cohort Studies; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Analysis; Tretinoin	2011
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood, 2011, Dec-15, Volume: 118, Issue:25 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin	2011
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Young Adult	2012
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. Haematologica, 2012, Volume: 97, Issue:11 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Tretinoin	2012
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 2012, Aug-23, Volume: 120, Issue:8 Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome; Tretinoin; Young Adult	2012
[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin	2013
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The New England journal of medicine, 2013, Jul-11, Volume: 369, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Oxides; Thrombocytopenia; Tretinoin; Young Adult	2013
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy. Leukemia research, 2013, Volume: 37, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Tretinoin; Young Adult	2013
Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Nov-20, Volume: 31, Issue:33 Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drugs, Chinese Herbal; Female; Fever; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Liver; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Remission Induction; Sulfides; Treatment Outcome; Tretinoin; Young Adult	2013
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. British journal of haematology, 2014, Volume: 165, Issue:4 Topics: Adult; Aged; Aminoglycosides; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dogs; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Oncogene Proteins, Fusion; Oxides; Platelet Count; Remission Induction; Risk; Treatment Outcome; Tretinoin; Young Adult	2014
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Oct-20, Volume: 32, Issue:30 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Quality of Life; Tretinoin	2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. British journal of haematology, 2015, Volume: 168, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Retrospective Studies; Survival Rate; Tretinoin	2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. British journal of haematology, 2015, Volume: 171, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Biomarkers, Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Tretinoin	2015
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet. Oncology, 2015, Volume: 16, Issue:13 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Denmark; Female; Humans; Idarubicin; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; New Zealand; Oncogene Proteins, Fusion; Oxides; Quality of Life; Real-Time Polymerase Chain Reaction; Time Factors; Treatment Outcome; Tretinoin; United Kingdom; Young Adult	2015
[Efficacy Analysis of Arsenic Trioxide Combined with All Trans Retinoic Acid for Acute Promyelocytic Leukemia]. Zhongguo shi yan xue ye xue za zhi, 2015, Volume: 23, Issue:5 Topics: Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin	2015
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia, 2016, Volume: 30, Issue:10 Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Italy; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Tretinoin; Young Adult	2016
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Feb-20, Volume: 35, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult	2017
The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Leukemia research, 2018, Volume: 65 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Blood Transfusion; Disseminated Intravascular Coagulation; Drugs, Chinese Herbal; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Platelet Transfusion; Retrospective Studies; Tretinoin; Young Adult	2018
Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. Leukemia research, 2018, Volume: 66 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Survival Rate; Tretinoin	2018
Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. BMC cancer, 2018, 04-03, Volume: 18, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Biomarkers; Case-Control Studies; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin	2018
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood, 2018, 09-27, Volume: 132, Issue:13 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Tretinoin; Young Adult	2018
Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. American journal of hematology, 2018, Volume: 93, Issue:12 Topics: Adolescent; Arsenic Trioxide; Child; Child, Preschool; Disease-Free Survival; Drugs, Chinese Herbal; Humans; Infant; Length of Stay; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin	2018
Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Trials, 2018, Sep-05, Volume: 19, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; China; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tretinoin; Young Adult	2018
Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia. Leukemia research, 2019, Volume: 83 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Models, Biological; Survival Rate; Tretinoin	2019
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Leukemia, 2020, Volume: 34, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Follow-Up Studies; Germany; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prospective Studies; Treatment Outcome; Tretinoin; Young Adult	2020
The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China. Cancer, 2020, 01-15, Volume: 126, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; China; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Hospitalization; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Remission Induction; Treatment Failure; Tretinoin	2020
Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death. Annals of hematology, 2020, Volume: 99, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin	2020
A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood advances, 2020, 04-28, Volume: 4, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2020
Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. British journal of haematology, 2020, Volume: 190, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Cognition; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Tretinoin	2020
[Therapies for newly diagnosed acute promyelocytic leukemia]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Treatment Outcome; Tretinoin	2020
Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 10-01, Volume: 39, Issue:28 Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; China; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Progression-Free Survival; Time Factors; Tretinoin	2021
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study. British journal of haematology, 2021, Volume: 195, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Prognosis; Retrospective Studies; Tretinoin; Young Adult	2021
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. JAMA oncology, 2022, Jan-01, Volume: 8, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Disease-Free Survival; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Tretinoin; Young Adult	2022
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia. Cancer chemotherapy and pharmacology, 2022, Volume: 90, Issue:1 Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2022
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). Blood cancer journal, 2022, 11-21, Volume: 12, Issue:11 Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2022
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group. Blood cancer journal, 2023, Dec-05, Volume: 13, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2023

Other Studies

373 other study(ies) available for arsenic trioxide and tretinoin

Article	Year
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Synthesis and antiproliferative activity of α-branched α,β-unsaturated ketones in human hematological and solid cancer cell lines. European journal of medicinal chemistry, 2015, Jun-15, Volume: 98 Topics: Cell Line, Tumor; Cell Proliferation; Hematologic Neoplasms; Humans; Ketones; Neoplasms; Quantitative Structure-Activity Relationship	2015
The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic. Experimental cell research, 1996, Dec-15, Volume: 229, Issue:2 Topics: Animals; Antibodies, Antinuclear; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autoantigens; Autoimmune Diseases; Cell Differentiation; CHO Cells; Cricetinae; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Transfection; Tretinoin; Tumor Suppressor Proteins	1996
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, May-01, Volume: 89, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Division; Cell Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Kinetics; Leukemia, Promyelocytic, Acute; Oxides; Phagocytosis; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Subcellular Fractions; Time Factors; Tretinoin; Tumor Cells, Cultured	1997
Arsenic and apoptosis in the treatment of acute promyelocytic leukemia. Journal of the National Cancer Institute, 1998, Jan-21, Volume: 90, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin	1998
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. Journal of the National Cancer Institute, 1998, Jan-21, Volume: 90, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transglutaminases; Tretinoin; Tumor Cells, Cultured	1998
Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood, 1998, Jun-01, Volume: 91, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Confocal; Oxides; Tretinoin; Tumor Cells, Cultured	1998
Acute promyelocytic leukemia: a curable disease. Leukemia, 1998, Volume: 12, Issue:12 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Karyotyping; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Research; Rome; Transcription Factors; Tretinoin; Tumor Suppressor Proteins	1998
Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. British journal of haematology, 1998, Volume: 103, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Oxides; T-Lymphocytes; Tretinoin; Tumor Cells, Cultured	1998
Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia. Journal of the National Cancer Institute, 1998, Dec-16, Volume: 90, Issue:24 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured	1998
Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene, 1999, Jan-28, Volume: 18, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured	1999
Arsenic: a new place? Pathology, 1999, Volume: 31, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	1999
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone marrow transplantation, 1999, Volume: 24, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Oxides; Recurrence; Transplantation, Autologous; Tretinoin	1999
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia. Annals of hematology, 1999, Volume: 78, Issue:7 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Feeding and Eating Disorders; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Metaphase; Middle Aged; Musculoskeletal Diseases; Oxides; Pain; Polymerase Chain Reaction; Recurrence; Tretinoin	1999
Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica, 1999, Volume: 84, Issue:11 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Bone Marrow; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Ligands; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Point Mutation; Protein Structure, Tertiary; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin	1999
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia, 2000, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Differentiation; DNA, Neoplasm; Electrophoresis, Agar Gel; Enzyme Precursors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Microscopy, Electron; Mitochondria; Mutation; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tretinoin; Tumor Cells, Cultured	2000
Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia, 2000, Volume: 14, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured	2000
Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid. British journal of haematology, 2000, Volume: 108, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Male; Oxides; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured	2000
Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells. Leukemia, 2000, Volume: 14, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thrombomodulin; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured	2000
Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports. Leukemia & lymphoma, 2000, Volume: 38, Issue:1-2 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pregnancy; Tretinoin	2000
Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia. Leukemia & lymphoma, 2000, Volume: 38, Issue:1-2 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin	2000
[Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:4 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Pleural Effusion; Remission Induction; Treatment Outcome; Tretinoin	2000
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:13 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Pleural Effusion; Syndrome; Tretinoin	2000
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2000, Aug-29, Volume: 97, Issue:18 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Translocation, Genetic; Transplantation, Heterologous; Tretinoin	2000
Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3). Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2000, Volume: 13, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytogenetics; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2000
Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochemical and biophysical research communications, 2000, Oct-14, Volume: 277, Issue:1 Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Differentiation; Cell Division; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasm Transplantation; Neuroblastoma; Oxides; RNA, Messenger; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured	2000
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood, 2001, Jan-01, Volume: 97, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Cell Culture Techniques; Cell Differentiation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Survival Rate; Tretinoin	2001
Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia. British journal of haematology, 2000, Volume: 111, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Christianity; Cytogenetic Analysis; Drug Therapy, Combination; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Middle Aged; Oxides; Platelet Count; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2000
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1998, Volume: 19, Issue:9 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin	1998
[In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1998, Volume: 19, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured	1998
Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thrombosis research, 2001, May-01, Volume: 102, Issue:3 Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Hemorrhage; Hemostasis; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin	2001
Hot on the TRAIL of acute promyelocytic leukemia. Nature medicine, 2001, Volume: 7, Issue:6 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Ligands; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Necrosis Factor-alpha	2001
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature medicine, 2001, Volume: 7, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Coculture Techniques; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Paracrine Communication; Proteins; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; TNF Receptor-Associated Factor 1; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2001
Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells. The hematology journal : the official journal of the European Haematology Association, 2001, Volume: 2, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; T-Lymphocytes; Tretinoin	2001
Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-01, Volume: 19, Issue:19 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin	2001
[Regulation of arsenic trioxide-inducing apoptosis]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1999, Volume: 20, Issue:5 Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; HL-60 Cells; Humans; Leukemia, Myeloid; Oligopeptides; Oxides; Tretinoin; Tumor Cells, Cultured	1999
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1999, Volume: 20, Issue:9 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Factor VIII; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured	1999
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). British journal of haematology, 2001, Volume: 115, Issue:1 Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arsenic Trioxide; Arsenicals; Central Nervous System; Combined Modality Therapy; Female; Gemtuzumab; Gene Rearrangement; Genes, MDR; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic; Tretinoin	2001
Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment. Chinese medical journal, 2000, Volume: 113, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin	2000
Long-term survey of outcome in acute promyelocytic leukemia. Chinese medical journal, 2000, Volume: 113, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Time Factors; Treatment Outcome; Tretinoin	2000
[Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells]. Chinese medical journal, 2000, Volume: 113, Issue:6 Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Oxides; Tretinoin	2000
[Drug resistance of acute promyelocytic leukemia (APL) to all-trans retinoic acid (ATRA) and its reversion]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2000, Volume: 22, Issue:2 Topics: Alprostadil; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Cell Survival; Drug Interactions; Drug Resistance; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Tretinoin	2000
Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3. Chinese medical journal, 2001, Volume: 114, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Caspases; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured	2001
Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells. Chinese medical journal, 2001, Volume: 114, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured	2001
[Mechanisms of arsenic trioxide-induced apoptosis in myeloma cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Dithiothreitol; Drug Interactions; Humans; Interferon-alpha; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured	2001
[A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia]. Zhonghua nei ke za zhi, 2001, Volume: 40, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin	2001
[Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins]. Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Division; Gene Expression; Growth Inhibitors; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin	2000
[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells]. Zhonghua yi xue za zhi, 2000, Volume: 80, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cells, Cultured; Female; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured; U937 Cells	2000
Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia. International journal of hematology, 2002, Volume: 75, Issue:1 Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Bone Marrow Transplantation; Combined Modality Therapy; Drug Resistance; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Tretinoin	2002
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2000, Volume: 21, Issue:5 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cycloheximide; Dactinomycin; Down-Regulation; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thromboplastin; Tretinoin; Tumor Cells, Cultured	2000
[Regulation of telomerase activity in HL-60 and NB4 cells by arsenic trioxide]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2000, Volume: 21, Issue:7 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Size; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Telomerase; Time Factors; Tretinoin; Tumor Cells, Cultured	2000
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. British journal of haematology, 2002, Volume: 117, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tretinoin	2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia, 2002, Volume: 16, Issue:4 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Monitoring; Electrocardiography; Female; Heart; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Remission Induction; Tretinoin	2002
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2002, Jul-09, Volume: 99, Issue:14 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Immunocompetence; Leukemia, Promyelocytic, Acute; Liposomes; Mice; Mice, Inbred C3H; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oncogene Proteins, Fusion; Oxides; Tretinoin	2002
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood, 2002, Aug-01, Volume: 100, Issue:3 Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Butyrates; Cell Differentiation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured	2002
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator. Thrombosis research, 2002, Apr-01, Volume: 106, Issue:1 Topics: Adolescent; Adult; Annexin A2; Antineoplastic Agents; AraC Transcription Factor; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Female; Fibrinolysin; Gene Expression Regulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen Activators; Repressor Proteins; RNA, Messenger; Tissue Plasminogen Activator; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured	2002
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. The Journal of experimental medicine, 2002, Nov-18, Volume: 196, Issue:10 Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Leukemia, Promyelocytic, Acute; Mice; Mice, Transgenic; Oxides; Signal Transduction; Theophylline; Tretinoin; Tumor Cells, Cultured	2002
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease. Annals of hematology, 2002, Volume: 81, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin	2002
[The expression of Fas, FasL and Bcl-2 on RMA cells during the process of apoptosis induced by chemotherapeutic drugs]. Zhongguo shi yan xue ye xue za zhi, 2002, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Dexamethasone; Etoposide; Fas Ligand Protein; fas Receptor; Gene Expression; Membrane Glycoproteins; Mice; Oxides; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured	2002
[In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thionucleotides; Tretinoin	2003
[Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Time Factors; Treatment Outcome; Tretinoin	2003
[Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2003, Volume: 24, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin	2003
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease. Haematologica, 2003, Volume: 88, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2003
Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. Leukemia, 2003, Volume: 17, Issue:9 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Tretinoin	2003
Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1. Oncogene, 2003, Dec-11, Volume: 22, Issue:57 Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Interferon-gamma; Leukemia, Promyelocytic, Acute; Oxides; Phosphoproteins; Promoter Regions, Genetic; Signal Transduction; STAT1 Transcription Factor; Superoxides; Trans-Activators; Tretinoin; Tumor Cells, Cultured	2003
Biography of Zhu Chen. Proceedings of the National Academy of Sciences of the United States of America, 2004, Apr-13, Volume: 101, Issue:15 Topics: Arsenic Trioxide; Arsenicals; China; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2004
[Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia]. Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin	2004
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. Leukemia, 2004, Volume: 18, Issue:7 Topics: Arsenic Trioxide; Arsenicals; Cell Culture Techniques; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Mutation, Missense; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Telomerase; Telomere; Tretinoin	2004
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leukemia research, 2004, Volume: 28, Issue:9 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Middle Aged; Oxides; Recurrence; Tretinoin	2004
Treatment of acute promyelocytic leukemia in children: arsenic or ATRA. Leukemia, 2004, Volume: 18, Issue:10 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin	2004
Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide. Annals of hematology, 2004, Volume: 83, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Oxidation-Reduction; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sodium Selenite; Sulfhydryl Compounds; Tretinoin	2004
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts. Leukemia & lymphoma, 2005, Volume: 46, Issue:2 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Humans; Ki-67 Antigen; Kinetics; Leukemia, Myeloid, Acute; Oxides; S Phase; Tretinoin; Tumor Cells, Cultured	2005
[Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 1997, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Intracellular Space; Leukemia; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Transport; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Suppressor Proteins	1997
[Effect of arsenic trioxide on drug transporting molecules in acute promyelocytic leukemia cell line]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:10 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Tretinoin; Vault Ribonucleoprotein Particles	2004
PRAM-1 potentiates arsenic trioxide-induced JNK activation. The Journal of biological chemistry, 2005, Mar-11, Volume: 280, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Kinetics; Leukemia, Promyelocytic, Acute; Microfilament Proteins; Oligopeptides; Oxides; Proteins; src Homology Domains; Tretinoin	2005
Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha. Oncogene, 2005, Mar-31, Volume: 24, Issue:14 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line; Cell Line, Tumor; Dimerization; DNA Primers; Mice; Oxides; Phosphorylation; Plasmids; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2005
Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells. Cell death and differentiation, 2005, Volume: 12, Issue:5 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Imidazoles; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oleanolic Acid; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Proteins	2005
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. British journal of haematology, 2005, Volume: 128, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bryostatins; Cell Cycle; Cell Line, Tumor; Cell Transformation, Neoplastic; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Macrolides; Myelopoiesis; Oxides; Tretinoin	2005
[Arsenic treatment for leukemia: new model of human cancer target treatment]. Zhonghua yi xue za zhi, 2005, Feb-23, Volume: 85, Issue:7 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Pyrimidines; Tretinoin	2005
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2005, May-24, Volume: 102, Issue:21 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Computational Biology; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Oligonucleotide Array Sequence Analysis; Oxides; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; Systems Biology; Tretinoin	2005
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia, 2005, Volume: 19, Issue:8 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin; Tumor Cells, Cultured	2005
[Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia]. Zhonghua yi xue za zhi, 2005, Apr-27, Volume: 85, Issue:16 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin	2005
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death. Leukemia, 2005, Volume: 19, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Telomerase; Telomere; Tretinoin; Tumor Cells, Cultured	2005
Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment. Internal medicine (Tokyo, Japan), 2005, Volume: 44, Issue:8 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Erythrocyte Count; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytes; Oxides; Platelet Count; Time Factors; Tretinoin	2005
[The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia]. Zhonghua nei ke za zhi, 2001, Volume: 40, Issue:12 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Down-Regulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin	2001
Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro. World journal of gastroenterology, 2005, Sep-28, Volume: 11, Issue:36 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Transferase; Humans; Lung Neoplasms; Oxides; Tretinoin	2005
Current management and new approaches in the treatment of APL. Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10 Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Monitoring; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin	2003
Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, Volume: 90, Issue:12 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cell Hypoxia; Cobalt; Deferoxamine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; U937 Cells	2005
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, Volume: 90, Issue:12 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Differentiation; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cobalt; Deferoxamine; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Oxygen; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; U937 Cells	2005
PLC-beta2 monitors the drug-induced release of differentiation blockade in tumoral myeloid precursors. Journal of cellular biochemistry, 2006, May-01, Volume: 98, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Enzyme Induction; Growth Inhibitors; Humans; Myeloid Progenitor Cells; Oxides; Phospholipase C beta; Tretinoin	2006
Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia, 2006, Volume: 20, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Gene Silencing; HL-60 Cells; Humans; Leukemia; Minor Histocompatibility Antigens; Oxides; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Tretinoin; Up-Regulation	2006
Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Biological & pharmaceutical bulletin, 2006, Volume: 29, Issue:5 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Oxides; Seafood; Tretinoin	2006
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. Haematologica, 2006, Volume: 91, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin	2006
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy. International journal of hematology, 2006, Volume: 83, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Radiography; Recurrence; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous; Tretinoin	2006
[Long-term survival analysis in 170 cases of acute promyelocytic leukemia]. Zhongguo shi yan xue ye xue za zhi, 2006, Volume: 14, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Tretinoin	2006
Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment. Leukemia & lymphoma, 2006, Volume: 47, Issue:7 Topics: Adolescent; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Risk; Skin; Tretinoin	2006
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood, 2007, Jan-15, Volume: 109, Issue:2 Topics: Acute Disease; Aquaporins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Oxides; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Tretinoin; Up-Regulation	2007
A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center. Leukemia research, 2007, Volume: 31, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin	2007
Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid. Annals of hematology, 2007, Volume: 86, Issue:4 Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Drug Therapy, Combination; Echocardiography; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin	2007
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Molecular cancer research : MCR, 2007, Volume: 5, Issue:1 Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Granulocytes; HL-60 Cells; Humans; Leukemia, Myeloid; Macrophages; Monocytes; Oxides; Protein Transport; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Tretinoin	2007
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer, 2007, Apr-01, Volume: 109, Issue:7 Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Tretinoin	2007
Current treatment of acute promyelocytic leukemia. Haematologica, 2007, Volume: 92, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Computer Systems; Disease Management; Drug Monitoring; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Mice; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Sensitivity and Specificity; Transfection; Tretinoin	2007
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica, 2007, Volume: 92, Issue:3 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ataxin-1; Ataxins; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Female; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Recombinant Fusion Proteins; Transfection; Tretinoin; Tumor Stem Cell Assay	2007
Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Annals of the New York Academy of Sciences, 2006, Volume: 1090 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; DNA Probes; Humans; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; Tretinoin	2006
[Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells]. Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin; Tumor Cells, Cultured	2007
Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells. Leukemia research, 2008, Volume: 32, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Genes, Mitochondrial; Glycolysis; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2008
Advances in management of acute promyelocytic leukemia with arsenic trioxide. Chinese journal of integrative medicine, 2007, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2007
Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid. Leukemia research, 2008, Volume: 32, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Enzyme-Linked Immunosorbent Assay; Gene Expression; Gene Expression Profiling; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Tretinoin	2008
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood, 2007, Dec-01, Volume: 110, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin	2007
[Effects of arsenic trioxide and ATRA on PLZF-RARalpha-positive U937 leukemic cells]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2007, Volume: 23, Issue:9 Topics: Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Leukemia; Nitroblue Tetrazolium; Oxidation-Reduction; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tetracycline; Tretinoin; U937 Cells	2007
Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. Haematologica, 2007, Volume: 92, Issue:12 Topics: Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Oxides; Phenylbutyrates; Syndrome; Tretinoin; Tumor Cells, Cultured	2007
Effect of the combination of ATRA, ATO and DNR on CD11b expression in NB4 cells. Leukemia research, 2008, Volume: 32, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Line, Tumor; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2008
All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia. Pediatric blood & cancer, 2008, Volume: 51, Issue:1 Topics: Adolescent; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Dysplastic Nevus Syndrome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin	2008
Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia. Leukemia, 2008, Volume: 22, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; CD11c Antigen; Cell Differentiation; Cyclooxygenase 1; Dinoprostone; Drug Therapy, Combination; Humans; Indomethacin; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Tretinoin; Tumor Cells, Cultured	2008
Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide. European journal of haematology, 2008, Volume: 81, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Tretinoin	2008
Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience. Pediatric blood & cancer, 2008, Volume: 51, Issue:2 Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome; Tretinoin	2008
Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Apoptosis : an international journal on programmed cell death, 2008, Volume: 13, Issue:7 Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Differentiation; Cell Line, Tumor; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4G; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tretinoin; Up-Regulation	2008
Acute promyelocytic leukemia: recent advances in diagnosis and management. Seminars in oncology, 2008, Volume: 35, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Salvage Therapy; Treatment Outcome; Tretinoin	2008
Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia. Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Multiple Primary; Oxides; Remission Induction; Tretinoin; Urinary Bladder Neoplasms	2008
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Analytical and bioanalytical chemistry, 2009, Volume: 393, Issue:2 Topics: Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Tretinoin	2009
Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells. Leukemia research, 2009, Volume: 33, Issue:7 Topics: alpha-Tocopherol; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Oxides; Tretinoin	2009
[Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008, Volume: 29, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Treatment Outcome; Tretinoin	2008
Curative strategies in acute promyelocytic leukemia. Hematology. American Society of Hematology. Education Program, 2008 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Growth Inhibitors; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Tretinoin	2008
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-01, Volume: 27, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Polymerase Chain Reaction; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin	2009
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin	2009
Curing APL: differentiation or destruction? Cancer cell, 2009, Jan-06, Volume: 15, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin	2009
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, Mar-03, Volume: 106, Issue:9 Topics: Aquaporins; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Prognosis; Survival Rate; Time Factors; Tretinoin	2009
[The significance of combined therapy of arsenic trioxide and all-trans retinoic acid in treating acute promyelocytic leukemia]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2009, Volume: 29, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Tretinoin; Young Adult	2009
[Immunofluorescence examination of CK-13 expression in cell line KB differentiated by all-trans retinoic acid or As2 O3]. Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2009, Volume: 44, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Differentiation; Fluorescent Antibody Technique; Humans; KB Cells; Keratin-13; Mouth Neoplasms; Oxides; Tretinoin	2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-01, Volume: 27, Issue:22 Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Bone Marrow; Cohort Studies; Confidence Intervals; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tretinoin	2009
Arsenic trioxide associated toothache. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:2 Topics: Arsenic Trioxide; Arsenicals; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Toothache; Tretinoin	2010
Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy. Leukemia & lymphoma, 2009, Volume: 50, Issue:7 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medical Oncology; Neoplasms, Second Primary; Oxides; Translocation, Genetic; Treatment Outcome; Tretinoin	2009
[Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:3 Topics: Adolescent; Adult; Aged; Annexin A2; Arsenic Trioxide; Arsenicals; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Tretinoin; Urokinase-Type Plasminogen Activator; Young Adult	2009
How I treat acute promyelocytic leukemia. Blood, 2009, Dec-10, Volume: 114, Issue:25 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Outcome Assessment, Health Care; Oxides; Practice Guidelines as Topic; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2009
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:11 Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myeloablative Agonists; Oncogene Proteins, Fusion; Oxides; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tretinoin; Young Adult	2009
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome. Blood, 2009, Dec-24, Volume: 114, Issue:27 Topics: Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL24; Chemokine CCL7; Chemokines; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Tretinoin; Tumor Cells, Cultured	2009
Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Nov-01, Volume: 66, Issue:21 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2009
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2009, Volume: 40, Issue:5 Topics: Abietanes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenanthrenes; Tretinoin	2009
[Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2009, Volume: 31, Issue:5 Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult	2009
Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia. International journal of hematology, 2010, Volume: 91, Issue:1 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin	2010
Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia. International journal of hematology, 2010, Volume: 91, Issue:1 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biopsy; Cheilitis; Female; Gangrene; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2010
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Etoposide; Factor Xa; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Glycoproteins; Microscopy, Confocal; Milk Proteins; Oxides; Phosphatidylserines; Thrombin; Thromboplastin; Tretinoin; Young Adult	2010
Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1. Molecular pharmacology, 2010, Volume: 77, Issue:5 Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dithiothreitol; Enzyme Activation; Genetic Variation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Oxides; Phosphorylation; Protein Kinases; Reactive Oxygen Species; RNA, Small Interfering; Tretinoin; U937 Cells	2010
Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients. Leukemia & lymphoma, 2010, Volume: 51, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Choriocarcinoma; Female; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neuroectodermal Tumors; Ovarian Neoplasms; Oxides; Prognosis; Tretinoin	2010
All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'. Leukemia & lymphoma, 2010, Volume: 51, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides; Prognosis; Tretinoin	2010
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. International journal of hematology, 2010, Volume: 91, Issue:5 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oncogenes; Oxides; Tretinoin	2010
Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience. International journal of hematology, 2010, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Child; Child, Preschool; China; Disseminated Intravascular Coagulation; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin	2010
CNS relapse in acute promyeloctyic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins	2010
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood, 2010, Sep-30, Volume: 116, Issue:13 Topics: Arsenic Trioxide; Arsenicals; Autophagy; Cell Differentiation; Cell Line, Tumor; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Serine-Threonine Kinases; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Small Interfering; Solubility; TOR Serine-Threonine Kinases; Transcription Factors; Tretinoin; Tumor Suppressor Proteins	2010
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells. Leukemia & lymphoma, 2010, Volume: 51, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinases; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured	2010
Autophagic degradation of an oncoprotein. Autophagy, 2010, Volume: 6, Issue:7 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tretinoin	2010
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer, 2011, Jan-01, Volume: 117, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Radiation-Induced; Oxides; Treatment Outcome; Tretinoin	2011
Arsenic trioxide (As₂O₃) inhibits murine WEHI-3 leukemia in BALB/c mice in vivo. Environmental toxicology, 2012, Volume: 27, Issue:6 Topics: Animals; Antigens, Differentiation; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Leukemia; Leukemia, Experimental; Macrophages; Male; Mice; Mice, Inbred BALB C; Oxides; Spleen; Tretinoin	2012
Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Survival Rate; Time Factors; Treatment Outcome; Tretinoin; Young Adult	2011
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10 Suppl 3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Risk Assessment; Treatment Outcome; Tretinoin	2010
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10 Suppl 3 Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Phenotype; Prognosis; Recurrence; Translocation, Genetic; Tretinoin	2010
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia. Leukemia research, 2011, Volume: 35, Issue:7 Topics: Adolescent; Adult; Aged; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Blotting, Western; Cell Proliferation; Female; Fibrinolysin; Fibrinolysis; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tissue Plasminogen Activator; Tretinoin; Young Adult	2011
Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary. Blood cells, molecules & diseases, 2011, Feb-15, Volume: 46, Issue:2 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Survival Rate; Time Factors; Treatment Failure; Tretinoin	2011
[A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:6 Topics: Abietanes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Oxides; Tretinoin; Young Adult	2010
Treatment of acute promyelocytic leukemia for older patients. Journal of the National Comprehensive Cancer Network : JNCCN, 2011, Volume: 9, Issue:3 Topics: Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Treatment Outcome; Tretinoin	2011
Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid. Annals of hematology, 2011, Volume: 90, Issue:12 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Recombinant Fusion Proteins; Tretinoin	2011
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18 Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Bone Marrow; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Mercaptopurine; Methotrexate; Oxides; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma, Myeloid; Soft Tissue Neoplasms; Tetrahydronaphthalenes; Tretinoin	2011
Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Archives of Iranian medicine, 2011, Volume: 14, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Cohort Studies; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult	2011
[Effects of As2O3 and all-trans retinoic acid on the growth of HeLa cell line and their relation with gene NDRG1]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin	2011
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Developing Countries; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis; Tretinoin	2011
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. Haematologica, 2011, Volume: 96, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin	2011
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia, 2012, Volume: 26, Issue:3 Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Electron Transport Complex I; Electron Transport Complex II; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Transgenic; Mitochondria; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Protein Stability; Rats; Reactive Oxygen Species; Transplantation, Isogeneic; Tretinoin	2012
Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination. Journal of cellular biochemistry, 2012, Volume: 113, Issue:5 Topics: Arsenic Trioxide; Arsenicals; Cell Nucleus; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA, Neoplasm; Genomic Instability; Histones; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Rad51 Recombinase; Recombinational DNA Repair; RNA Interference; Transcription Factors; Tretinoin; Tumor Suppressor Proteins	2012
Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia. Pediatric hematology and oncology, 2012, Volume: 29, Issue:2 Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Benzoates; Child; Drug Administration Schedule; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin	2012
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine. Leukemia research, 2012, Volume: 36, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Primary Myelofibrosis; Remission Induction; Survivors; Tretinoin	2012
[Regulation of all-trans retinoic acid and arsenic trioxide on CD44v6 expression in NB4 cells]. Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Oxides; Signal Transduction; Tretinoin	2012
Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia. International journal of hematology, 2012, Volume: 95, Issue:5 Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Multivariate Analysis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Transcription, Genetic; Treatment Outcome; Tretinoin	2012
Mitochondrial myopathy caused by arsenic trioxide therapy. Blood, 2012, May-03, Volume: 119, Issue:18 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Mitochondria, Muscle; Mitochondrial Myopathies; Oxides; Tretinoin	2012
Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks. Leukemia research, 2012, Volume: 36, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Staging; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult	2012
[Expression of homeobox A9 in myeloid leukemia cell line HL-60 and effect of drugs on its expression]. Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:2 Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia, Myeloid; Oxides; RNA, Messenger; Tretinoin	2012
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer, 2012, Dec-01, Volume: 118, Issue:23 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; SEER Program; Time Factors; Tretinoin; United States	2012
Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype. Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Middle Aged; Oxides; Retrospective Studies; Tretinoin	2012
ATRA plus arsenic gets another "A" in APL. Blood, 2012, Aug-23, Volume: 120, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin	2012
Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A. Oncology reports, 2012, Volume: 28, Issue:5 Topics: Antigens, CD34; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Biological Transport; Biomarkers, Tumor; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Lewis X Antigen; Oxides; Tretinoin; Up-Regulation	2012
[microRNAs expression profile in acute promyelocytic leukemia cell differentiation induced by all-trans retinoic acid and arsenic trioxide]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2012, Volume: 33, Issue:7 Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Tretinoin; Tumor Cells, Cultured	2012
High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leukemia research, 2013, Volume: 37, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Tretinoin	2013
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group. Annals of hematology, 2013, Volume: 92, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk; Thioguanine; Treatment Outcome; Tretinoin	2013
Prognostic significance of CD44v6/v7 in acute promyelocytic leukemia. Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Female; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Tumor Cells, Cultured; Young Adult	2012
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia. Hematology (Amsterdam, Netherlands), 2012, Volume: 17, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Young Adult	2012
[Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells]. Zhongguo shi yan xue ye xue za zhi, 2012, Volume: 20, Issue:6 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plant Proteins; Tretinoin	2012
All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. Leukemia, 2013, Volume: 27, Issue:7 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Tretinoin	2013
A case report of acute myeloid leukemia after liver transplantation. Acta haematologica, 2013, Volume: 129, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Hepatitis B; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mitoxantrone; Oxides; Tretinoin	2013
Role of arsenic trioxide in acute promyelocytic leukemia. Current treatment options in oncology, 2013, Volume: 14, Issue:2 Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Tretinoin	2013
Mees lines and Beau lines. Cutis, 2013, Volume: 91, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Nail Diseases; Oxides; Remission Induction; Tretinoin	2013
Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report. Annals of hematology, 2014, Volume: 93, Issue:2 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tretinoin	2014
Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia. Oncogene, 2014, May-22, Volume: 33, Issue:21 Topics: Antigen Presentation; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Subunits; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Trans-Activators; Transcription Factors; Transcriptional Activation; Transcriptome; Tretinoin; Tumor Escape; Tumor Suppressor Proteins	2014
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results. Leukemia & lymphoma, 2014, Volume: 55, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome; Tretinoin	2014
Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse. Acta haematologica, 2013, Volume: 130, Issue:4 Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Sarcoma, Myeloid; Testicular Neoplasms; Testis; Tretinoin; WT1 Proteins	2013
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. Cancer science, 2013, Volume: 104, Issue:10 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Retrospective Studies; Salvage Therapy; Tetrahydronaphthalenes; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Young Adult	2013
Targeting agents alone to cure acute promyelocytic leukemia. The New England journal of medicine, 2013, Jul-11, Volume: 369, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin	2013
A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses? European journal of haematology, 2013, Volume: 91, Issue:5 Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome; Tretinoin	2013
3Omics: a web-based systems biology tool for analysis, integration and visualization of human transcriptomic, proteomic and metabolomic data. BMC systems biology, 2013, Jul-23, Volume: 7 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Profiling; Humans; Internet; Leukemia, Promyelocytic, Acute; Metabolomics; Oxides; Proteomics; Statistics as Topic; Systems Biology; Tretinoin; Urinalysis	2013
Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia? Blood, 2013, Sep-19, Volume: 122, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2013
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3. Neoplasma, 2013, Volume: 60, Issue:6 Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tretinoin; Young Adult	2013
Overcoming treatment resistance in acute promyelocytic leukemia and beyond. Oncotarget, 2013, Volume: 4, Issue:8 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin	2013
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Hematological oncology, 2014, Volume: 32, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult	2014
Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience. European journal of haematology, 2013, Volume: 91, Issue:6 Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Neoplasm, Residual; Oxides; Prognosis; Treatment Outcome; Tretinoin	2013
Arsenic trioxide combination improves survival in APL. The Lancet. Oncology, 2013, Volume: 14, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Remission Induction; Survival Rate; Tretinoin	2013
The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5 Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Codon; Extracellular Signal-Regulated MAP Kinases; Genes, p53; Glioblastoma; Humans; Molecular Sequence Data; Mutation; Neoplastic Stem Cells; Oxides; Tretinoin	2014
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nature medicine, 2014, Volume: 20, Issue:2 Topics: Animals; Arsenic Trioxide; Arsenicals; Computational Biology; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Mice; Microarray Analysis; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription Factors; Tretinoin; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2014
Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child. Pediatric hematology and oncology, 2014, Volume: 31, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin	2014
Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia. European journal of haematology, 2014, Volume: 93, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Survival Analysis; Tretinoin	2014
PML nuclear bodies mediate the therapeutic response of APL cells. Cancer discovery, 2014, Volume: 4, Issue:3 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Tretinoin	2014
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies. Journal of internal medicine, 2014, Volume: 276, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Signal Transduction; Tretinoin	2014
The effect to IL-3Ralpha, downstream PI3k/Akt signaling of all-trans retinoic acid and arsenic trioxide in NB4 cells. Die Pharmazie, 2014, Volume: 69, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Humans; Interleukin-13 Receptor alpha1 Subunit; Leukemia, Myeloid; Neoplasm Proteins; Oncogene Protein v-akt; Oxides; Phosphatidylinositol 3-Kinases; RNA, Messenger; Signal Transduction; Tretinoin	2014
Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia. International journal of hematology, 2014, Volume: 100, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin	2014
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide. Leukemia research, 2014, Volume: 38, Issue:8 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrimidines; Tretinoin; Up-Regulation	2014
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. British journal of haematology, 2014, Volume: 167, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Fetus; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Tretinoin; Young Adult	2014
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells. British journal of cancer, 2014, Aug-26, Volume: 111, Issue:5 Topics: Arsenic Trioxide; Arsenicals; Cell Survival; Drug Synergism; Glutathione; Heme Oxygenase-1; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin; Tumor Cells, Cultured	2014
All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells. Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Carcinoma, Hepatocellular; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Oxides; Tretinoin	2014
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leukemia & lymphoma, 2015, Volume: 56, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Tretinoin; Young Adult	2015
ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. PloS one, 2014, Volume: 9, Issue:8 Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult	2014
A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia. Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:10 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Tretinoin	2014
Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report. The Journal of international medical research, 2014, Volume: 42, Issue:6 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 21; Humans; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutagenesis, Insertional; Oncogene Proteins, Fusion; Oxides; Sex Chromosome Disorders; Translocation, Genetic; Treatment Outcome; Tretinoin; XYY Karyotype	2014
Resistance to therapy in acute promyelocytic leukemia. The New England journal of medicine, 2014, Sep-18, Volume: 371, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oncogene Proteins, Fusion; Oxides; Recurrence; Tretinoin	2014
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation. Blood, 2014, Dec-11, Volume: 124, Issue:25 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Chlorocebus aethiops; COS Cells; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Nude; Mice, Transgenic; Oncogene Proteins, Fusion; Oxides; Promoter Regions, Genetic; Protein Binding; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sumoylation; Transcriptional Activation; Tretinoin	2014
Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European journal of haematology, 2015, Volume: 95, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Monte Carlo Method; Oxides; Quality-Adjusted Life Years; Recurrence; Treatment Failure; Treatment Outcome; Tretinoin	2015
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood, 2015, May-28, Volume: 125, Issue:22 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oncogene Proteins; Oxides; Tretinoin; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays	2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood, 2015, May-28, Volume: 125, Issue:22 Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Myeloid, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Proteolysis; Tretinoin; Tumor Cells, Cultured	2015
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PloS one, 2015, Volume: 10, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Prospective Studies; Recurrence; Transcription Factors; Tretinoin; Tumor Suppressor Proteins; Young Adult	2015
[Antileukemic]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia; Oxides; Remission Induction; Tetrahydronaphthalenes; Tretinoin	2015
ATRA and As₂O₃ regulate differentiation of human hematopoietic stem cells into granulocyte progenitor via alteration of HoxB8 expression. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:6 Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cells, Cultured; Female; Fetal Blood; Gene Expression Regulation; Granulocyte Precursor Cells; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Infant, Newborn; Oxides; Pregnancy; RNA, Messenger; Tretinoin	2015
Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Aug-15, Volume: 21, Issue:16 Topics: Animals; Arsenic Trioxide; Arsenicals; Camptothecin; Cell Differentiation; Cell Movement; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Mice; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polyethylene Glycols; Tretinoin	2015
[The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Tretinoin	2015
Lessons taught by acute promyelocytic leukemia cure. Lancet (London, England), 2015, Jul-18, Volume: 386, Issue:9990 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Suppressor Protein p53	2015
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective. PloS one, 2015, Volume: 10, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin	2015
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. EBioMedicine, 2015, Volume: 2, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Epigenesis, Genetic; Female; Genes, Modifier; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Oxides; Prognosis; Treatment Outcome; Tretinoin; Young Adult	2015
Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia. EBioMedicine, 2015, Volume: 2, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin	2015
Chemotherapy-free treatment of acute promyelocytic leukemia. Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:8 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2015
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Markov Chains; Models, Economic; Oxides; Treatment Outcome; Tretinoin; United States	2015
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. Leukemia research, 2015, Volume: 39, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Cost Savings; Cost-Benefit Analysis; Direct Service Costs; Female; Health Care Costs; Hospitals, University; Humans; Length of Stay; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Tretinoin; Young Adult	2015
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia. Blood, 2015, Nov-26, Volume: 126, Issue:22 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Quality of Life; Survival Rate; Tretinoin	2015
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. Cancer genetics, 2015, Volume: 208, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 17; Female; Humans; Isochromosomes; Leukemia, Promyelocytic, Acute; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Treatment Outcome; Tretinoin	2015
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era? Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12 Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Oxides; Proportional Hazards Models; Treatment Outcome; Tretinoin; Young Adult	2015
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice. Blood cancer journal, 2015, Dec-11, Volume: 5 Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Disease Models, Animal; DNA; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin	2015
[History of acute promyelocytic leukemia]. La Revue du praticien, 2015, Volume: 65, Issue:8 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2015
Genital vasculitis secondary to all-trans-retinoic-acid. BMJ case reports, 2016, Jan-20, Volume: 2016 Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Genitalia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Vasculitis	2016
Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells. International journal of oncology, 2016, Volume: 48, Issue:3 Topics: Animals; Anthracyclines; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; CD11b Antigen; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred BALB C; Middle Aged; Oxides; Tamoxifen; Tretinoin	2016
Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype. Hematology/oncology and stem cell therapy, 2017, Volume: 10, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Bone Marrow; Disseminated Intravascular Coagulation; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukopenia; Male; Oxides; Treatment Outcome; Tretinoin; Young Adult	2017
Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. PloS one, 2016, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Platelet Count; Prothrombin Time; Retrospective Studies; Tretinoin; Young Adult	2016
Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells. Life sciences, 2016, Mar-15, Volume: 149 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Oxides; Tretinoin	2016
The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines. Skin pharmacology and physiology, 2016, Volume: 29, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Lymphoma, T-Cell, Cutaneous; Oxides; Tretinoin	2016
Targeted Therapy Alone for Acute Promyelocytic Leukemia. The New England journal of medicine, 2016, Mar-24, Volume: 374, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Follow-Up Studies; Humans; Intention to Treat Analysis; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin	2016
PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Cells; Child; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Female; Follow-Up Studies; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; India; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oncogene Proteins, Fusion; Oxides; Phytohemagglutinins; Prognosis; Translocation, Genetic; Tretinoin	2016
Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo. Oncotarget, 2016, Jul-19, Volume: 7, Issue:29 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polysaccharides; Tretinoin; Xenograft Model Antitumor Assays	2016
Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient. Annals of hematology, 2016, Volume: 95, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Lung Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Postoperative Complications; Skin Neoplasms; Tretinoin	2016
Induction treatments for acute promyelocytic leukemia: a network meta-analysis. Oncotarget, 2016, Nov-01, Volume: 7, Issue:44 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Network Meta-Analysis; Oxides; Randomized Controlled Trials as Topic; Tretinoin; Young Adult	2016
Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome? Leukemia & lymphoma, 2017, Volume: 58, Issue:7 Topics: Acute Disease; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Oxides; Pericarditis; Remission Induction; Tretinoin	2017
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatric blood & cancer, 2017, Volume: 64, Issue:8 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin	2017
[Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy]. Deutsche medizinische Wochenschrift (1946), 2017, Volume: 142, Issue:2 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Dyspnea; Female; Fever; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Leukocytosis; Lung Diseases; Oxides; Risk Factors; Severity of Illness Index; Syndrome; Treatment Outcome; Tretinoin	2017
RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner. Oncotarget, 2017, Feb-14, Volume: 8, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cyclic AMP; Flow Cytometry; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Ligands; Naphthalenes; Nitro Compounds; Oncogene Proteins, Fusion; Oxides; Protein Binding; Proteolysis; Retinoid X Receptor alpha; Styrenes; Tretinoin	2017
Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia. Annals of hematology, 2017, Volume: 96, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Tretinoin	2017
Poisoning the Devil. Cell, 2017, 02-09, Volume: 168, Issue:4 Topics: Arsenic Trioxide; Arsenicals; China; France; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2017
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens. Annals of hematology, 2017, Volume: 96, Issue:5 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Case-Control Studies; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Galectin 3; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult	2017
Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways. Leukemia & lymphoma, 2017, Volume: 58, Issue:10 Topics: Apoptosis; Arsenic Trioxide; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Signal Transduction; Tretinoin	2017
Bruising and abnormal leucocytes on a blood film--a haematological emergency. BMJ (Clinical research ed.), 2017, 03-23, Volume: 356 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Contusions; Gingival Hemorrhage; Humans; Lethargy; Leukemia, Promyelocytic, Acute; Leukocytes; Male; Oxides; Tretinoin; Young Adult	2017
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β. Annals of hematology, 2017, Volume: 96, Issue:6 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; CD11c Antigen; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imidazoles; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Time Factors; Tretinoin; Tumor Necrosis Factor-alpha; U937 Cells	2017
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells. Cell death & disease, 2017, 05-11, Volume: 8, Issue:5 Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Interferon Regulatory Factors; Leukemia, Promyelocytic, Acute; Male; Monocytes; Neoplasm Proteins; Oxides; Tretinoin	2017
Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress. Leukemia, 2018, Volume: 32, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Line; Cell Line, Tumor; Endoplasmic Reticulum Stress; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2018
Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematology/oncology and stem cell therapy, 2019, Volume: 12, Issue:3 Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Promyelocytic, Acute; Male; Rituximab; Tretinoin	2019
HOXA9 is critical in the proliferation, differentiation, and malignancy of leukaemia cells both in vitro and in vivo. Cell biochemistry and function, 2017, Volume: 35, Issue:7 Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Down-Regulation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia; Male; Mice; Mice, Nude; MicroRNAs; Oxides; RNA Interference; RNA, Messenger; Transplantation, Heterologous; Tretinoin	2017
Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL. Journal of leukocyte biology, 2017, Volume: 102, Issue:6 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 12; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Nucleus; Death-Associated Protein Kinases; Gene Knockdown Techniques; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Protein Stability; Signal Transduction; Transcription, Genetic; Tretinoin; Tumor Protein p73	2017
Severe myopericarditis following induction therapy with idarubicin and transretinoic acid in a patient with acute promyelocytic leukemia. Medicina clinica, 2018, 06-22, Volume: 150, Issue:12 Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cardiovascular Agents; Chest Pain; Drug Substitution; Echocardiography; Electrocardiography; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Myocarditis; Pericarditis; Remission Induction; Tretinoin	2018
[Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia]. Zhongguo shi yan xue ye xue za zhi, 2017, Volume: 25, Issue:6 Topics: Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin	2017
[Successful treatment of acute promyelocytic leukaemia without chemotherapy and blood transfusion]. Ugeskrift for laeger, 2018, 01-15, Volume: 180, Issue:3 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Religion and Medicine; Treatment Outcome; Treatment Refusal; Tretinoin	2018
[Acute Promyelocytic Leukemia - A Rare, Life-Threatening Disease with High Healing Chance]. Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:3 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Rare Diseases; Tretinoin	2018
Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia. Medicine, 2018, Volume: 97, Issue:8 Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Sarcoma, Myeloid; Suppuration; Tretinoin	2018
ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia. Nucleic acids research, 2018, 04-20, Volume: 46, Issue:7 Topics: Animals; Apoptosis; Arsenic Trioxide; Caspases; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Resistance, Neoplasm; Humans; Intercalating Agents; Leukemia, Promyelocytic, Acute; Mice; Molecular Docking Simulation; Oncogene Proteins, Fusion; Phenanthridines; Promyelocytic Leukemia Protein; Proteolysis; Retinoic Acid Receptor alpha; Tretinoin; Xenograft Model Antitumor Assays	2018
Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Cancer, 2018, 06-01, Volume: 124, Issue:11 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Ascorbic Acid; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Disease-Free Survival; Female; Headache; Hematopoietic Stem Cell Transplantation; Hong Kong; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Risk Factors; Severity of Illness Index; Survival Analysis; Time Factors; Transplantation, Autologous; Tretinoin; Young Adult	2018
Influence of acute promyelocytic leukemia therapeutic drugs on nuclear pore complex density and integrity. Biochemical and biophysical research communications, 2018, 05-15, Volume: 499, Issue:3 Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitosis; Nuclear Envelope; Nuclear Pore; Oxides; Permeability; Tretinoin	2018
Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia. British journal of haematology, 2019, Volume: 184, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Point-of-Care Systems; Prospective Studies; Syndrome; Tretinoin; Ultrasonography	2019
Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Disease Progression; Disseminated Intravascular Coagulation; Drug Substitution; Humans; Leukemia, Promyelocytic, Acute; Male; Treatment Outcome; Tretinoin	2018
Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia. BMJ case reports, 2018, May-02, Volume: 2018 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biopsy; Consolidation Chemotherapy; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Skin; Tretinoin	2018
Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nature communications, 2018, 05-24, Volume: 9, Issue:1 Topics: 5'-Nucleotidase; Animals; Antineoplastic Agents; Arsenic Trioxide; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mutation; Promyelocytic Leukemia Protein; Recurrence; Retinoic Acid Receptor alpha; Tretinoin	2018
[Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia]. Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Retrospective Studies; Tretinoin	2018
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. Annals of hematology, 2018, Volume: 97, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult	2018
Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells. Oncology reports, 2018, Volume: 40, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imides; Leukemia, Promyelocytic, Acute; Oxides; Pyrans; Quinolines; Tretinoin; Wnt Signaling Pathway	2018
Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. British journal of haematology, 2019, Volume: 185, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Female; Hematologic Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin	2019
Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nature communications, 2018, 08-09, Volume: 9, Issue:1 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Proliferation; Female; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Transplantation; Neoplasms; NIMA-Interacting Peptidylprolyl Isomerase; Proteomics; Signal Transduction; Tretinoin	2018
Diffuse Pulmonary Alveolar Hemorrhage Secondary to All-Trans-Retinoic Acid in Acute Promyelocytic Leukemia. Chinese medical journal, 2018, 10-05, Volume: 131, Issue:19 Topics: Adult; Arsenic Trioxide; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Tretinoin	2018
Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia. Leukemia & lymphoma, 2019, Volume: 60, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Prognosis; Recurrence; Retreatment; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin	2019
Microgranular variant of acute promyelocytic leukemia with cytoplasmic projections resembling micromegakaryocytes. Blood, 2018, 11-22, Volume: 132, Issue:21 Topics: Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Megakaryocytes; Tretinoin	2018
Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid. Leukemia & lymphoma, 2019, Volume: 60, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Blood Transfusion; Hospitalization; Humans; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin	2019
Acute promyelocytic leukaemia presenting as necrotising fasciitis of the perineum (Fournier gangrene). BMJ case reports, 2018, 12-07, Volume: 11, Issue:1 Topics: Adult; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Fasciitis, Necrotizing; Fournier Gangrene; Humans; Leukemia, Promyelocytic, Acute; Male; Perineum; Remission Induction; Treatment Outcome; Tretinoin	2018
Flexural Eruption Associated With Arsenic Trioxide Therapy in a Patient With Acute Promyelocytic Leukemia. JAMA dermatology, 2019, Mar-01, Volume: 155, Issue:3 Topics: Aged; Arsenic Trioxide; Biopsy, Needle; Drug Eruptions; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Male; Remission, Spontaneous; Risk Assessment; Treatment Outcome; Tretinoin	2019
Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide. Cancer genetics, 2019, Volume: 231-232 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Child; Chromosome Breakpoints; Disease-Free Survival; Female; Humans; India; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Oncogene Proteins, Fusion; RNA, Messenger; Treatment Outcome; Tretinoin; Young Adult	2019
Successful Treatment With ATRA and Arsenic Trioxide for a Child With Down Syndrome and Acute Promyelocytic Leukemia. Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Down Syndrome; Female; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2020
Identification of a point mutation PML Biochemical and biophysical research communications, 2019, 04-09, Volume: 511, Issue:3 Topics: Antineoplastic Agents; Arsenic Trioxide; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Point Mutation; Sumoylation; Tretinoin	2019
A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide. British journal of cancer, 2019, Volume: 120, Issue:11 Topics: Aged; Arsenic Trioxide; Drug Resistance, Neoplasm; Gene Fusion; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Nuclear Proteins; Nucleophosmin; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Tretinoin	2019
Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell research, 2019, Volume: 29, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease Models, Animal; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neoplasms, Experimental; Tretinoin; Tumor Cells, Cultured; U937 Cells	2019
Effect of combination of all-trans retinoic acid and arsenic trioxide on apoptosis of acute promyelocytic leukemia cells. Cellular and molecular biology (Noisy-le-Grand, France), 2019, Apr-30, Volume: 65, Issue:4 Topics: Apoptosis; Arsenic Trioxide; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Interleukin-6; Leukemia, Promyelocytic, Acute; Prognosis; Quality of Life; Tretinoin; Tumor Necrosis Factor-alpha	2019
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer, 2019, 09-15, Volume: 125, Issue:18 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Blood Component Transfusion; Female; Gemtuzumab; Humans; Induction Chemotherapy; Intensive Care Units; Intubation, Intratracheal; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Patient Transfer; Retrospective Studies; Risk Factors; Serum Albumin; Tretinoin; Water-Electrolyte Imbalance; Young Adult	2019
Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells. Scientific reports, 2019, 07-01, Volume: 9, Issue:1 Topics: Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Line, Tumor; Chemokine CCL2; CpG Islands; Demethylation; GTP-Binding Proteins; Humans; Leukemia, Promyelocytic, Acute; Promoter Regions, Genetic; Protein Glutamine gamma Glutamyltransferase 2; Receptors, Retinoic Acid; Transcriptome; Transglutaminases; Tretinoin	2019
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. American journal of hematology, 2019, Volume: 94, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bone Marrow; Clone Cells; Disease Progression; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Promyelocytic Leukemia Protein; Protein Domains; Recurrence; Remission Induction; Reproducibility of Results; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Tretinoin	2019
Bone Marrow Findings in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide. American journal of clinical pathology, 2019, 10-07, Volume: 152, Issue:5 Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Biopsy; Bone Marrow; Bone Marrow Cells; Erythroid Cells; Female; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Megakaryocytes; Middle Aged; Myeloid Cells; Myeloid Progenitor Cells; Treatment Outcome; Tretinoin; Young Adult	2019
[Acute kidney failure in differentiation syndrome: a possible complication during therapy with differentiating agents for acute promyelocytic leukemia. A case report]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2019, Jul-24, Volume: 36, Issue:4 Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Arsenic Trioxide; Dexamethasone; Edema; Fever of Unknown Origin; Humans; Hypotension; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Renal Dialysis; Respiratory Distress Syndrome; Syndrome; Tretinoin	2019
[Effect of Chromosomal Karyotype on the Prognosis of Patients with Acute Promyelocytic Leukemia in Condition of the Maintenance Treatment Based on Arsenic Trioxide]. Zhongguo shi yan xue ye xue za zhi, 2019, Volume: 27, Issue:5 Topics: Arsenic Trioxide; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Prognosis; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin	2019
A Rare Morphology Resembling APL with t (11;12) (p15;q13) in Acute Myeloid Leukemia: Case Report and Literature Review. Clinical laboratory, 2019, Oct-01, Volume: 65, Issue:10 Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 12; Humans; Leukemia, Myeloid; Male; Oncogene Proteins, Fusion; Review Literature as Topic; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult	2019
Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case Series. Hematology/oncology and stem cell therapy, 2020, Volume: 13, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin	2020
[All-trans retinoic acid/arsenic trioxide combination therapy for a patient with acute promyelocytic leukemia on dialysis]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2019, Volume: 60, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Polycystic Kidney Diseases; Remission Induction; Renal Dialysis; Treatment Outcome; Tretinoin	2019
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective? Cancer, 2020, 01-15, Volume: 126, Issue:2 Topics: Arsenic Trioxide; Arsenicals; China; Cost-Benefit Analysis; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2020
The Effect of Arsenic Trioxide on All-trans Retinoic Acid Binding to Human Serum Albumin. Journal of fluorescence, 2019, Volume: 29, Issue:6 Topics: Arsenic Trioxide; Binding Sites; Energy Transfer; Humans; Serum Albumin, Human; Spectrometry, Fluorescence; Thermodynamics; Tretinoin	2019
Acute Promyelocytic Leukemia With Sudden Vision Loss. JAMA ophthalmology, 2020, 02-01, Volume: 138, Issue:2 Topics: Arsenic Trioxide; Blindness; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retinal Detachment; Tretinoin	2020
Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France. British journal of haematology, 2020, Volume: 188, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Child; Child, Preschool; Disease-Free Survival; Drug Tolerance; Female; France; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Retrospective Studies; Survival Rate; Tretinoin	2020
[Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients]. Zhongguo shi yan xue ye xue za zhi, 2020, Volume: 28, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin	2020
A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient. Annals of hematology, 2021, Volume: 100, Issue:1 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Humans; Kidney Transplantation; Male; Renal Insufficiency, Chronic; Sarcoma, Myeloid; Tissue Donors; Transplant Recipients; Tretinoin	2021
Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Pregnancy; Recurrence; Tretinoin; Young Adult	2020
JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL). International journal of hematology, 2020, Volume: 111, Issue:6 Topics: Antineoplastic Agents; Arsenic Trioxide; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Practice Guidelines as Topic; Tretinoin	2020
Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum. British journal of haematology, 2020, Volume: 190, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; COVID-19; COVID-19 Drug Treatment; Humans; Leukemia, Promyelocytic, Acute; Male; SARS-CoV-2; Tretinoin	2020
Arsenic trioxide and all-trans retinoic acid suppress the expression of FLT3-ITD. Leukemia & lymphoma, 2020, Volume: 61, Issue:11 Topics: Arsenic Trioxide; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Prognosis; Tretinoin	2020
First report of successful management of acute promyelocytic leukemia in a pregnant female with All-Trans-Retinoic Acid and Arsenic Trioxide-based induction regimen. Blood cells, molecules & diseases, 2020, Volume: 85 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Tretinoin; Young Adult	2020
Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report. The Journal of international medical research, 2020, Volume: 48, Issue:9 Topics: Acute Disease; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Pancreatitis; Tretinoin; Wernicke Encephalopathy	2020
Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia. Leukemia & lymphoma, 2021, Volume: 62, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2021
Role of cofilin‑1 in arsenic trioxide‑induced apoptosis of NB4‑R1 cells. Molecular medicine reports, 2020, Volume: 22, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Death; Cofilin 1; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Oxides; Proteomics; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Tretinoin; Tumor Cells, Cultured	2020
Effects of different autophagy inhibitors on sensitizing KG-1 and HL-60 leukemia cells to chemotherapy. IUBMB life, 2021, Volume: 73, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Cell Proliferation; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin; Tumor Cells, Cultured	2021
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia. British journal of haematology, 2021, Volume: 192, Issue:2 Topics: Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Transplantation, Autologous; Tretinoin	2021
[Acute promyelocytic leukemia recurrence diagnosed due to granulocytic sarcoma of the external auditory canal]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:11 Topics: Arsenic Trioxide; Ear Canal; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Recurrence; Sarcoma, Myeloid; Tretinoin	2020
Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia. Leukemia & lymphoma, 2021, Volume: 62, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2021
Towards Optimizing Risk-adapted Treatment of APML in ATRA/ATO Era: How Can Prediction of Early Mortality Help? Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Prognosis; Risk Assessment; Risk Factors; Tretinoin	2021
Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Biomarkers, Tumor; Bone Marrow; Disease Management; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Prognosis; Treatment Outcome; Tretinoin; Young Adult	2021
A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic. Cancer, 2021, 08-15, Volume: 127, Issue:16 Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2021
Multidisciplinary corroboration in differentiation syndrome: a case report. Journal of medical case reports, 2021, May-05, Volume: 15, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Promyelocytic, Acute; Syndrome; Tretinoin	2021
Mutational profile of ZBTB16-RARA-positive acute myeloid leukemia. Cancer medicine, 2021, Volume: 10, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Bone Marrow; Child; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Disseminated Intravascular Coagulation; DNA Helicases; DNA-Binding Proteins; Female; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nuclear Proteins; Oncogene Proteins, Fusion; Prognosis; Promyelocytic Leukemia Zinc Finger Protein; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin	2021
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study. Haematologica, 2021, 12-01, Volume: 106, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Prospective Studies; Remission Induction; Risk Assessment; Treatment Outcome; Tretinoin; Young Adult	2021
Arsenic and all- Haematologica, 2021, 12-01, Volume: 106, Issue:12 Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2021
Crosstalk between hnRNP K and SET in ATRA-induced differentiation in acute promyelocytic leukemia. FEBS open bio, 2021, Volume: 11, Issue:7 Topics: Animals; Arsenic Trioxide; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Tretinoin	2021
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin	2022
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience. British journal of haematology, 2021, Volume: 195, Issue:2 Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Arsenic Trioxide; Case-Control Studies; Child; Child, Preschool; Combined Modality Therapy; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult	2021
All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status. Current medical science, 2021, Volume: 41, Issue:3 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutation; Prognosis; Tretinoin; Young Adult	2021
Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study. Blood advances, 2021, 07-27, Volume: 5, Issue:14 Topics: Arsenic Trioxide; Hospitals; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Tretinoin	2021
Diagnosis of Acute Promyelocytic Leukemia After Presentation to Neuro-Ophthalmology. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2022, 03-01, Volume: 42, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Ophthalmology; Papilledema; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult	2022
Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis. Cancer, 2022, 01-15, Volume: 128, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sociodemographic Factors; Treatment Outcome; Tretinoin; United States	2022
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia. Blood advances, 2022, 01-25, Volume: 6, Issue:2 Topics: Animals; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin	2022
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients. Leukemia & lymphoma, 2022, Volume: 63, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2022
Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment. Annals of hematology, 2022, Volume: 101, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Necrosis; Tretinoin	2022
Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax: A case report. Medicine, 2021, Dec-03, Volume: 100, Issue:48 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Ecchymosis; Female; Humans; Leukemia, Promyelocytic, Acute; Mutation; Proto-Oncogene Proteins c-bcl-2; Recurrence; Salvage Therapy; Sulfonamides; Treatment Outcome; Tretinoin	2021
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia. Journal of pediatric hematology/oncology, 2022, 05-01, Volume: 44, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cord Blood Stem Cell Transplantation; Female; Gemtuzumab; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2022
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. Blood cancer journal, 2022, 01-31, Volume: 12, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Treatment Outcome; Tretinoin	2022
Venetoclax for arsenic-resistant acute promyelocytic leukaemia. British journal of haematology, 2022, Volume: 197, Issue:5 Topics: Arsenic; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Tretinoin	2022
Cup-shaped nuclei in acute promyelocytic leukaemia. British journal of haematology, 2022, Volume: 197, Issue:4 Topics: Arsenic Trioxide; Cell Nucleus; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2022
Alternate application of all-trans-retinoic acid and arsenic trioxide combined with idarubicin/daunorubicin in treatment of acute promyelocytic leukemia. Pakistan journal of pharmaceutical sciences, 2022, Volume: 35, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Cohort Studies; Daunorubicin; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Prospective Studies; Tretinoin	2022
Arsenic trioxide induces the differentiation of retinoic acid-resistant neuroblastoma cells via upregulation of HoxC9. Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2022, Volume: 31, Issue:8 Topics: Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Line, Tumor; Homeodomain Proteins; Humans; Neuroblastoma; Proteomics; Tretinoin; Up-Regulation	2022
Extracellular Traps Increase Burden of Bleeding by Damaging Endothelial Cell in Acute Promyelocytic Leukaemia. Frontiers in immunology, 2022, Volume: 13 Topics: Arsenic Trioxide; Endothelial Cells; Extracellular Traps; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Tretinoin	2022
Do high-mobility group box 1 gene polymorphisms affect the incidence of differentiation syndrome in acute promyelocytic leukemia? Molecular biology reports, 2022, Volume: 49, Issue:7 Topics: Arsenic Trioxide; Cytokines; HMGB1 Protein; Humans; Incidence; Leukemia, Promyelocytic, Acute; Polymorphism, Genetic; Syndrome; Tretinoin	2022
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia. The Korean journal of internal medicine, 2022, Volume: 37, Issue:4 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Cytarabine; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Recurrence; Remission Induction; Treatment Outcome; Tretinoin	2022
[Acute Myeloid Leukemia - Update 2022]. Deutsche medizinische Wochenschrift (1946), 2022, Volume: 147, Issue:17 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Azacitidine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin	2022
Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging. Analytical chemistry, 2022, 10-11, Volume: 94, Issue:40 Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Protein Aggregates; Sulfur; Tretinoin	2022
Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα. Acta pharmacologica Sinica, 2023, Volume: 44, Issue:4 Topics: Antineoplastic Agents; Arsenic Trioxide; HeLa Cells; Humans; Hyperthermia, Induced; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Promyelocytic Leukemia Zinc Finger Protein; Tretinoin	2023
CPSF6-RARG-positive acute myeloid leukaemia resembles acute promyelocytic leukaemia but is insensitive to retinoic acid and arsenic trioxide. Pathology, 2023, Volume: 55, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Retinoic Acid Receptor gamma; Tretinoin	2023
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia. Journal of hematology & oncology, 2022, 10-18, Volume: 15, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin	2022
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe. British journal of haematology, 2023, Volume: 200, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin	2023
The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage. International journal of hematology, 2023, Volume: 117, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Humans; Intracranial Hemorrhages; Leukemia, Promyelocytic, Acute; Prospective Studies; Retrospective Studies; Tretinoin	2023
Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study. British journal of haematology, 2023, Volume: 201, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin	2023
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia. International journal of hematology, 2023, Volume: 117, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin	2023
A global study for acute myeloid leukemia with RARG rearrangement. Blood advances, 2023, 07-11, Volume: 7, Issue:13 Topics: Arsenic Trioxide; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Tretinoin	2023
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα. Cell death and differentiation, 2023, Volume: 30, Issue:5 Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Transcription Factors; Tretinoin; Ubiquitination	2023
Tocotrienols-enriched Self-nanoemulsifying Drug Delivery System Enhances the Antileukemic Activity of All-trans Retinoic Acid but not Electrocardiogram Alterations Evoked by Its Combination with Arsenic Trioxide. AAPS PharmSciTech, 2023, Mar-14, Volume: 24, Issue:3 Topics: Animals; Arsenic Trioxide; Electrocardiography; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tocotrienols; Tretinoin	2023
[Devil with angel wings - when vitamin A saves lives]. Deutsche medizinische Wochenschrift (1946), 2023, Volume: 148, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Disseminated Intravascular Coagulation; Humans; Leukemia, Promyelocytic, Acute; Male; Tretinoin; Vitamin A	2023
Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death. Cell death & disease, 2023, 03-28, Volume: 14, Issue:3 Topics: Arsenic Trioxide; Arsenicals; Cell Death; Humans; Integrins; Leukemia, Promyelocytic, Acute; Mechanistic Target of Rapamycin Complex 2; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases; Tretinoin	2023
Report of PRPF19 as a novel partner of RARG and the recurrence of interposition-type fusion in variant acute promyelocytic leukemia. Hematological oncology, 2023, Volume: 41, Issue:4 Topics: Arsenic Trioxide; DNA Repair Enzymes; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Receptors, Retinoic Acid; RNA Splicing Factors; Tretinoin	2023
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity. British journal of haematology, 2023, Volume: 202, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Repressor Proteins; Retinoic Acid Receptor alpha; Tretinoin	2023
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse. Blood cancer journal, 2023, 06-22, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin	2023
The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells. Biochemical pharmacology, 2023, Volume: 214 Topics: Arsenic Trioxide; Caspase 3; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Tretinoin	2023
ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2. International journal of molecular sciences, 2023, Jun-30, Volume: 24, Issue:13 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calpain; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Oxides; Protein Glutamine gamma Glutamyltransferase 2; Reactive Oxygen Species; Tretinoin	2023
Angiogenesis, coagulation, and fibrinolytic markers in acute promyelocytic leukemia (NB4): An evaluation of melatonin effects. Journal of pineal research, 2023, Volume: 75, Issue:3 Topics: Arsenic Trioxide; Endothelial Cells; Humans; Leukemia, Promyelocytic, Acute; Melatonin; Tretinoin	2023
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen. Leukemia & lymphoma, 2023, Volume: 64, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin	2023
Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid. Leukemia research, 2023, Volume: 134 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Thrombosis; Tretinoin	2023